Novel promoter sequences and methods thereof for enhancing protein production in Bacillus cells
By introducing and modifying novel promoter sequences in Bacillus species cells, the problem of insufficient protein yield in existing technologies has been solved, resulting in a significant improvement in protein productivity and meeting the needs of industrial protein production.
Patent Information
- Application Number
- CN201980090475.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-11-28
- Filing Date
- 2019-11-25
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2039-11-25
Smart Images

Figure CN113366108B_ABST
Abstract
Description
Technical Field
[0001] The present disclosure generally relates to the fields of bacteriology, microbiology, molecular biology, genetics, enzymology, industrial protein production, etc. More particularly, certain embodiments of the present disclosure relate to novel promoter sequences and methods for obtaining enhanced protein production phenotypes in Bacillus sp. (host) cells. As described herein, when the novel promoter sequences of the present disclosure are effectively linked to a gene (or open reading frame) encoding a target protein, they are particularly suitable for large-scale production of industrially relevant proteins.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS
[0003] This application claims the benefit of U.S. Provisional Patent Application No. 62 / 772,363, filed on November 28, 2018, which is incorporated herein by reference in its entirety.
[0004] References to sequence listings
[0005] The electronically submitted content of the text file sequence listing named "NB41318-WO-PCT_SequenceListing.txt" was created on November 21, 2019 and is 176KB in size, which is hereby incorporated by reference in its entirety. Background Art
[0006] Gram-positive bacteria such as Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens, etc. have excellent fermentation properties and high yields (e.g., up to 25 g / L culture; Van Dijl and Hecker, 2013), and are therefore often used as microbial factories for the production of industrially relevant proteins. For example, Bacillus subtilis is well known for its production of α-amylase (Jensen et al., 2000; Raul et al., 2014) and proteases (Brode et al., 1996) necessary for the food, textile, laundry, medical / dental devices (cleaning), membranes (cleaning), pharmaceutical industries, etc. (Westers et al., 2004). Because these non-pathogenic Gram-positive bacteria produce proteins that are completely free of toxic byproducts such as lipopolysaccharides (LPS), also known as endotoxins, they have received “Qualified as Safety” (QPS) status from the European Food Safety Authority and many of their products have received “Generally Recognized as Safe” (GRAS) status from the U.S. Food and Drug Administration (Olempska-Beer et al., 2006; Earl et al., 2008; Caspers et al., 2010).
[0007] Therefore, the production of proteins (e.g., enzymes, antibodies, receptors, peptides, etc.) in microbial host cells is of particular interest in the field of biotechnology. Likewise, the optimization of host cells for the production and / or secretion of one or more target proteins is of high relevance, particularly in the context of industrial biotechnology, where slight improvements in protein yields are of great significance when proteins are produced in large industrial quantities. More particularly, Bacillus licheniformis and Bacillus subtilis are exemplary Bacillus species (host) cells of high industrial importance, and therefore, it is highly desirable to have the ability to genetically modify and engineer such host cells to obtain enhanced / increased protein expression / production for the construction of new and improved Bacillus species production strains.
[0008] For example, the recombinant production of a target protein (e.g., an enzyme) encoded by a gene (or open reading frame (ORF)) is typically accomplished by constructing an expression cassette (i.e., a construct / vector / cassette suitable for a given host cell), wherein the polynucleotide (sequence) encoding the target protein is placed downstream (3') of a promoter (nucleic acid) sequence and operably linked to the promoter (nucleic acid) sequence. Thus, the promoter sequence is placed upstream (5') of the gene (or ORF) and operably linked to the gene (or ORF), which is located downstream (3') of the promoter sequence (i.e., in operative combination).
[0009] Likewise, the expression cassette is introduced into a host cell by various techniques (e.g., transformation), wherein the expression / production of the desired protein of interest (POI) can be achieved by culturing the (transformed) host cell under appropriate conditions required for the expression / production of the POI. For example, International PCT Publication No. WO 2013 / 086219 generally discloses a promoter, an expression vector, a microorganism, and a method for producing a polynucleotide encoding a protein of interest, the polynucleotide comprising a ribosomal promoter derived from Bacillus subtilis.
[0010] Although many promoters for expressing genes in host cells are known, there is still a continuous and unmet need in the art for novel promoter (nucleic acid) sequences. More particularly, such continuous and unmet needs include, but are not limited to, the identification of novel promoter (nucleic acid) sequences, their enhanced promoter function, their increased promoter activity, enhanced protein production phenotypes, etc. As presented, described and exemplified below, the present disclosure relates to such highly desirable and unmet needs for obtaining novel promoter sequences and constructing their Bacillus species host cells (e.g., protein production (host) cells, cell factories) comprising enhanced protein production phenotypes, etc. Summary of the invention
[0011] The present disclosure generally relates to compositions and methods for producing and constructing Bacillus sp. cells (e.g., protein-producing host cells, cell factories) with increased protein production phenotypes, etc. More particularly, certain embodiments of the present disclosure relate to novel promoter (nucleic acid) sequences, expression cassettes comprising such novel promoters, and modified Bacillus sp. (progeny) cells thereof, comprising an enhanced protein productivity phenotype.
[0012] Therefore, certain embodiments of the present disclosure are related promoter nucleic acid sequences. In certain embodiments, the promoter nucleic acid sequence comprises at least 90% sequence identity to SEQ ID NO: 39 and comprises at least one mutation selected from the group consisting of: thymine (T) at nucleotide position 30 of SEQ ID NO: 39, thymine (T) at nucleotide position 89 of SEQ ID NO: 39, guanine (G) at nucleotide position 90 of SEQ ID NO: 39, and thymine (T) at nucleotide position 91 of SEQ ID NO: 39. In other embodiments, the promoter nucleic acid sequence of the present disclosure comprises at least two mutations selected from the group consisting of: T at nucleotide position 30 of SEQ ID NO: 39, T at nucleotide position 89 of SEQ ID NO: 39, G at nucleotide position 90 of SEQ ID NO: 39, and T at nucleotide position 91 of SEQ ID NO: 39. In other embodiments, the promoter nucleic acid sequence comprises at least three mutations selected from the group consisting of: T at nucleotide position 30 of SEQ ID NO:39, T at nucleotide position 89 of SEQ ID NO:39, G at nucleotide position 90 of SEQ ID NO:39, and T at nucleotide position 91 of SEQ ID NO:39. In certain other embodiments, the promoter nucleic acid sequence comprises at least four mutations, the mutations comprising T at nucleotide position 30 of SEQ ID NO:39, T at nucleotide position 89 of SEQ ID NO:39, G at nucleotide position 90 of SEQ ID NO:39, and T at nucleotide position 91 of SEQ ID NO:39. In other embodiments, the promoter nucleic acid sequence comprises SEQ ID NO:40. In other embodiments, the promoter nucleic acid sequence of the present disclosure comprises a gene or open reading frame (ORF) encoding a protein of interest (POI) located downstream (3′) of the promoter and operably connected to the promoter. In certain embodiments, the protein of interest (POI) is an enzyme. In other embodiments, the enzyme is a hydrolase. In yet other embodiments, the promoter sequence comprises one or more nucleotides located upstream (5′) and operably linked thereto. In certain embodiments, the promoter sequence is operably linked (3′) downstream to a native aprE 5′-UTR sequence or a modified aprE 5′-UTR sequence thereof. In certain embodiments, the native aprE 5′-UTR sequence comprises SEQ ID NO: 85.
[0013] Therefore, certain other embodiments of the present disclosure relate to a promoter nucleic acid sequence comprising SEQ ID NO:40, SEQ ID NO:58, or SEQ ID NO:59. In specific embodiments, the promoter nucleic acid sequence comprising SEQ ID NO:40, SEQ ID NO:58, or SEQ ID NO:59 further comprises a gene or ORF encoding a protein of interest (POI) located downstream (3') of the promoter and operably linked to the promoter. In certain embodiments, the POI is an enzyme. In other embodiments, the enzyme is a hydrolase. In another embodiment, the promoter nucleic acid sequence comprising SEQ ID NO:40, SEQ ID NO:58, or SEQ ID NO:59 further comprises one or more nucleotides located upstream (5') and operably linked thereto. In another embodiment, the promoter nucleic acid sequence comprising SEQ ID NO:40, SEQ ID NO:58, or SEQ ID NO:59 is operably linked (3') to a downstream native aprE 5'-UTR sequence or a modified aprE 5'-UTR sequence thereof. In another embodiment, the native aprE 5′-UTR sequence comprises SEQ ID NO:85.
[0014] Certain other embodiments of the present disclosure relate to a polynucleotide sequence that hybridizes to SEQ ID NO: 60 under stringent hybridization conditions, wherein the hybridizing polynucleotide sequence comprises at least one mutation at a nucleotide position selected from 30, 89, 90, or 91, relative to the equivalent nucleotide position 30, 89, 90, or 91 of SEQ ID NO: 39. In certain embodiments, the polynucleotide sequence that hybridizes under stringent hybridization conditions comprises SEQ ID NO: 40. In another embodiment, the polynucleotide sequence that hybridizes under stringent hybridization conditions comprises SEQ ID NO: 58. In other embodiments, the polynucleotide sequence that hybridizes under stringent hybridization conditions comprises SEQ ID NO: 59. In certain other embodiments, the polynucleotide sequence that hybridizes to SEQ ID NO: 60 under stringent hybridization conditions further comprises a gene or ORF encoding a protein of interest (POI) located downstream (3′) of the promoter and operably linked to the promoter. In certain embodiments, the POI is an enzyme. In other embodiments, the enzyme is a hydrolase. In other embodiments, the polynucleotide further comprises one or more nucleotides located upstream (5′) and operably linked to it. In certain other embodiments, the polynucleotide sequence that hybridizes to SEQ ID NO:60 under stringent hybridization conditions is operably linked to the (3') downstream native aprE 5'-UTR sequence or a modified aprE 5'-UTR sequence thereof. In specific embodiments, the native aprE 5'-UTR sequence comprises SEQ ID NO:85.
[0015] Therefore, certain other embodiments relate to genetically modified Bacillus species cells comprising novel promoter sequences disclosed herein. Certain other embodiments relate to genetically modified Bacillus species cells comprising novel polynucleotide sequences disclosed herein. Other embodiments relate to expression cassettes comprising novel promoters of the present disclosure or expression cassettes comprising novel polynucleotides of the present disclosure. Still other embodiments relate to modified Bacillus species cells comprising expression cassettes of the present disclosure.
[0016] Thus, certain other embodiments relate to a mutant Bacillus subtilis cell comprising a promoter nucleic acid sequence that hybridizes to SEQ ID NO:60 under stringent hybridization conditions, wherein the mutant promoter sequence comprises at least one mutation at a nucleotide position selected from 30, 89, 90, or 91, relative to the equivalent nucleotide position 30, 89, 90, or 91 of SEQ ID NO:39.
[0017] In other embodiments, the disclosure relates to a promoter region nucleic acid sequence comprising a (5′) upstream promoter sequence operably linked to a (3′) downstream 5′-UTR sequence, wherein the promoter sequence comprises at least 90% sequence identity to SEQ ID NO: 82 and comprises a thymine (T) at nucleotide position 72 of SEQ ID NO: 82, a guanine (G) at nucleotide position 73 of SEQ ID NO: 82, and a thymine (T) at nucleotide position 74 of SEQ ID NO: 82. In certain embodiments, the promoter region nucleic acid sequence comprises a native 5′-UTR sequence or a modified 5′-UTR sequence. In certain embodiments, the 5′-UTR sequence is the native amyL 5′-UTR sequence of SEQ ID NO: 84, or a variant amyL 5′-UTR sequence thereof. In another embodiment, the promoter region nucleic acid sequence comprises the native aprE 5′-UTR sequence of SEQ ID NO: 85, or a variant aprE 5′-UTR sequence thereof.
[0018] Thus, other embodiments relate to a promoter region nucleic acid sequence comprising SEQ ID NO:65. Another embodiment relates to a promoter region nucleic acid sequence comprising SEQ ID NO:67. In another embodiment, the promoter region nucleic acid sequence comprising SEQ ID NO:65 further comprises a gene or open reading frame (ORF) encoding a protein of interest (POI) located downstream (3′) of the promoter region and operatively linked to the promoter region. In certain embodiments, the POI is an enzyme. In another embodiment, the enzyme is a hydrolase. In other embodiments, the promoter region sequence further comprises one or more nucleotides located upstream (5′) and operatively linked to it.
[0019] In certain other embodiments, the present disclosure relates to a modified Bacillus licheniformis amyL promoter derived from a native Bacillus licheniformis amyL promoter comprising a nucleotide sequence of SEQ ID NO: 82, wherein the modified promoter comprises at least 90% sequence identity to SEQ ID NO: 82 and comprises a thymine (T) at nucleotide position 72 of SEQ ID NO: 82, a guanine (G) at nucleotide position 73 of SEQ ID NO: 82, and a thymine (T) at nucleotide position 74 of SEQ ID NO: 82. In another embodiment, the modified amyL promoter comprises a gene or open reading frame (ORF) encoding a protein of interest (POI) located downstream (3') of the promoter and operably linked to the promoter. In specific embodiments, the POI is an enzyme. In other embodiments, the enzyme is a hydrolase. In another embodiment, the promoter further comprises one or more nucleotides located upstream (5') and operably linked to it.
[0020] Thus, certain other embodiments relate to polynucleotide sequences that hybridize to the polynucleotide sequence of SEQ ID NO: 65 or its complement under stringent hybridization conditions. Thus, other embodiments relate to polynucleotide sequences that hybridize to SEQ ID NO: 67 or its complement under stringent hybridization conditions. Another embodiment relates to polynucleotide sequences that hybridize to SEQ ID NO: 83 or its complement under stringent hybridization conditions.
[0021] Other embodiments relate to modified Bacillus sp. cells comprising the novel promoter regions of the present disclosure.
[0022] Certain embodiments relate to a modified Bacillus sp. cell comprising a modified promoter of SEQ ID NO:83.
[0023] Accordingly, certain other embodiments relate to expression cassettes comprising the novel promoter regions of the present disclosure.In certain embodiments, the expression cassette comprises a modified Bacillus licheniformis amyL promoter.
[0024] Accordingly, certain other embodiments of the present disclosure relate to methods for enhanced protein production in a modified Bacillus sp. cell, the method comprising: (a) introducing a polynucleotide expression cassette into a parent Bacillus sp. cell, wherein the expression cassette comprises a promoter sequence located upstream (5′) and operably linked to a gene or open reading frame (ORF) encoding a protein of interest (POI), wherein the promoter comprises at least 90% identity to SEQ ID NO: 39 and comprises at least one modification selected from the group consisting of: a T at nucleotide position 30 of SEQ ID NO: 39, a T at nucleotide position 89 of SEQ ID NO: 39, a G at nucleotide position 90 of SEQ ID NO: 39, and a G at nucleotide position 110 of SEQ ID NO: 111. NO: 39; (b) isolating the modified cell comprising the introduced expression construct from step (a); and (c) fermenting the modified cell of step (b) under conditions suitable for producing the POI, wherein the modified cell of step (c) produces an increased amount of the POI relative to an equivalent Bacillus species cell, the equivalent Bacillus species cell comprising a polynucleotide expression cassette comprising a promoter sequence located upstream (5′) of the same gene or ORF encoding the same POI and operably linked to the same gene or ORF encoding the same POI, wherein the promoter comprises SEQ ID NO: 39. In certain embodiments, the promoter comprises at least two mutations selected from the group consisting of: a T at nucleotide position 30 of SEQ ID NO: 39, a T at nucleotide position 89 of SEQ ID NO: 39, a G at nucleotide position 90 of SEQ ID NO: 39, and a T at nucleotide position 91 of SEQ ID NO: 39. In other embodiments, the promoter comprises at least three mutations selected from the group consisting of: T at nucleotide position 30 of SEQ ID NO: 39, T at nucleotide position 89 of SEQ ID NO: 39, G at nucleotide position 90 of SEQ ID NO: 39, and T at nucleotide position 91 of SEQ ID NO: 39. In another embodiment, the promoter comprises at least four mutations, the mutations comprising T at nucleotide position 30 of SEQ ID NO: 39, T at nucleotide position 89 of SEQ ID NO: 39, G at nucleotide position 90 of SEQ ID NO: 39, and T at nucleotide position 91 of SEQ ID NO: 39. In other embodiments of the method, the POI is an enzyme. In another embodiment of the method, the enzyme is a hydrolase. In another embodiment of the method, the promoter further comprises one or more nucleotides located upstream (5′) and operably linked thereto.In certain embodiments, the promoter sequence is operably linked (3') downstream to a native aprE 5'-UTR sequence or a modified aprE 5'-UTR sequence thereof. In other embodiments of the methods, the native aprE 5'-UTR sequence comprises SEQ ID NO:85.
[0025] Certain other embodiments of the present disclosure relate to methods for enhanced protein production in a modified Bacillus sp. cell, the method comprising: (a) introducing a polynucleotide expression cassette into a parent Bacillus sp. cell, wherein the expression cassette comprises an upstream promoter region comprising at least 90% sequence identity to SEQ ID NO: 65 and having a thymine (T) at nucleotide position 72 of SEQ ID NO: 65, a guanine (G) at nucleotide position 73 of SEQ ID NO: 65, and a thymine (T) at nucleotide position 74 of SEQ ID NO: 65. NO:65, wherein the upstream promoter region is operably linked to a gene or open reading frame (ORF) encoding a protein of interest (POI); (b) isolating a modified cell comprising the introduced expression cassette from step (a); and (c) fermenting the modified cell of step (b) under conditions suitable for producing the POI, wherein the modified cell of step (c) produces an increased amount of the POI relative to an equivalent Bacillus species cell, the equivalent Bacillus species cell comprising an introduced polynucleotide expression cassette comprising an upstream promoter region, the upstream promoter region comprising at least 90% sequence identity to SEQ ID NO:65 and having an adenine (A) at nucleotide position 72 of SEQ ID NO:65, a thymine (T) at nucleotide position 73 of SEQ ID NO:65, and a guanine (G) at nucleotide position 74 of SEQ ID NO:65, wherein the upstream promoter region is operably linked to the same gene or ORF encoding the same POI. In certain embodiments of the method, the POI is an enzyme. In other embodiments, the enzyme is a hydrolase.
[0026] In another embodiment, the present disclosure relates to a method for enhanced protein production in a modified Bacillus sp. cell, the method comprising: (a) introducing a polynucleotide expression cassette into a parent Bacillus sp. cell, wherein the expression cassette comprises an upstream promoter region comprising at least 90% sequence identity to SEQ ID NO: 67 and having a thymine (T) at nucleotide position 72 of SEQ ID NO: 65, a guanine (G) at nucleotide position 73 of SEQ ID NO: 65, and a thymine (T) at nucleotide position 74 of SEQ ID NO: 65, and a guanine (G) at nucleotide position 75 of SEQ ID NO: 65. NO:65, wherein the upstream promoter region is operably linked to a gene or open reading frame (ORF) encoding a protein of interest (POI); (b) isolating a modified cell comprising the introduced expression cassette from step (a); and (c) fermenting the modified cell of step (b) under conditions suitable for producing the POI, wherein the modified cell of step (c) produces an increased amount of the POI relative to an equivalent Bacillus species cell, the equivalent Bacillus species cell comprising an introduced polynucleotide expression cassette containing an upstream promoter region, the upstream promoter region comprising at least 90% sequence identity to SEQ ID NO:67 and having an adenine (A) at nucleotide position 72 of SEQ ID NO:65, a thymine (T) at nucleotide position 73 of SEQ ID NO:65, and a guanine (G) at nucleotide position 74 of SEQ ID NO:65, wherein the upstream promoter region is operably linked to the same gene or ORF encoding the same POI. In certain embodiments of the method, the POI is an enzyme. In other embodiments, the enzyme is a hydrolase.
[0027] In another embodiment, the present disclosure relates to a method for enhanced protein production in a modified Bacillus sp. cell, the method comprising: (a) introducing a polynucleotide expression cassette into a parent Bacillus sp. cell, wherein the expression cassette comprises an upstream promoter comprising at least 90% sequence identity to SEQ ID NO: 83 and having a thymine (T) at nucleotide position 72 of SEQ ID NO: 83, a guanine (G) at nucleotide position 73 of SEQ ID NO: 83, and a thymine (T) at nucleotide position 74 of SEQ ID NO: 83. NO:83, wherein the upstream promoter is operably linked to a gene or open reading frame (ORF) encoding a protein of interest (POI); (b) isolating a modified cell comprising the introduced expression cassette from step (a); and (c) fermenting the modified cell of step (b) under conditions suitable for producing the POI, wherein the modified cell of step (c) produces an increased amount of the POI relative to an equivalent Bacillus species cell, the equivalent Bacillus species cell comprising an introduced polynucleotide expression cassette containing an upstream promoter, the upstream promoter comprising at least 90% sequence identity to SEQ ID NO:83 and having an adenine (A) at nucleotide position 72 of SEQ ID NO:83, a thymine (T) at nucleotide position 73 of SEQ ID NO:83, and a guanine (G) at nucleotide position 74 of SEQ ID NO:83, wherein the upstream promoter is operably linked to the same gene or ORF encoding the same POI. In certain embodiments of the method, the POI is an enzyme. In other embodiments, the enzyme is a hydrolase. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 The nucleic acid sequence alignment of the native Bacillus subtilis rrnIp2 promoter (SEQ ID NO:39), the novel (synthetic) rrnIp2-1 promoter (SEQ ID NO:40), the novel (synthetic) rrnIp2-2 promoter (SEQ ID NO:58), and the novel (synthetic) rrnIp2-3 promoter (SEQ ID NO:59) is presented. Figure 1 As shown, the -35 and -10 promoter sequence regions are Underlined nucleotides The putative transcription start site (TSS) is indicated by Bold Underline The nucleotides are indicated by double underlined “ G ” nucleotides are used to help visualize the TSS.
[0029] Figure 2 The native rrnIp2 promoter (SEQ ID NO: 39) and its complementary sequence (SEQ ID NO: 60; Figure 2 A), synthetic rrnIp2-1 promoter (SEQ ID NO: 40) and its complementary sequence (SEQ ID NO: 61; Figure 2 B), synthetic rrnIp2-2 promoter (SEQ ID NO: 58) and its complementary sequence (SEQ ID NO: 62; Figure 2 C), and rrnIp2-3 promoter (SEQ ID NO: 59) and its complementary sequence (SEQ ID NO: 63; Figure 2 D).
[0030] Figure 3 The nucleic acid sequence alignment of the native Bacillus licheniformis amyL promoter region (PamyL-1; SEQ ID NO: 64) and the novel (synthetic) amyL promoter region (PamyL-2; SEQ ID NO: 65) is presented. Figure 3 As shown, the -35 and -10 promoter sequence regions are Underlined nucleotides denoted by 5′-UTR sequences are indicated by nucleotides in italics, and the putative transcription start site (TSS) is indicated by nucleotides in bold, while the double-underlined “ G ” nucleotides were used to help visualize the TSS of PamyL-1 (relative to PamyL-2).
[0031] Figure 4 An alignment of the native Bacillus licheniformis amyL promoter sequence (SEQ ID NO: 82) and the synthetic amyL promoter sequence (SEQ ID NO: 83) is shown, with the putative transcription start site (TSS) indicated by bold nucleotides and the underlined " G The nucleotides are used to help visualize the TSS of the native amyL promoter (vs. the synthetic amyL promoter).
[0032] Figure 5 The nucleic acid sequence alignment of the synthetic PamyL-3 promoter region (SEQ ID NO: 66) and the synthetic PamyL-4 promoter region (SEQ ID NO: 67) is presented. Figure 5 As shown, the putative transcription start site (TSS) is indicated by nucleotides in bold, followed by the 5′-UTR sequence indicated by nucleotides in italics, and the double-underlined “ G ” nucleotides were used to help visualize the TSS of PamyL-3 (relative to PamyL-4).
[0033] Brief description of biological sequence
[0034] SEQ ID NO: 1 is a synthetic nucleic acid sequence encoding Cas9 protein.
[0035] SEQ ID NO: 2 is the amino acid sequence of the N-terminal nuclear localization signal (NLS) sequence.
[0036] SEQ ID NO: 3 is the amino acid sequence of the C-terminal NLS sequence.
[0037] SEQ ID NO: 4 is an amino acid sequence comprising a deca-histidine (10-H) tag.
[0038] SEQ ID NO: 5 is a nucleic acid sequence comprising the Bacillus subtilis aprE promoter.
[0039] SEQ ID NO:6 is the Cas9 forward primer nucleic acid sequence.
[0040] SEQ ID NO:7 is the Cas9 reverse primer nucleic acid sequence.
[0041] SEQ ID NO: 8 is the nucleic acid sequence of the backbone of plasmid pKB320.
[0042] SEQ ID NO:9 is the nucleic acid sequence of plasmid pKB320.
[0043] SEQ ID NO: 10 is the pKB320 forward primer nucleic acid sequence.
[0044] SEQ ID NO: 11 is the pKB320 reverse primer nucleic acid sequence.
[0045] SEQ ID NO: 12 is the Cas9 "reverse sequencing primer 1" nucleic acid sequence.
[0046] SEQ ID NO: 13 is the Cas9 "reverse sequencing primer 2" nucleic acid sequence.
[0047] SEQ ID NO: 14 is the Cas9 "forward sequencing primer 1" nucleic acid sequence.
[0048] SEQ ID NO: 15 is the Cas9 "forward sequencing primer 2" nucleic acid sequence.
[0049] SEQ ID NO: 16 is the Cas9 "forward sequencing primer 3" nucleic acid sequence.
[0050] SEQ ID NO: 17 is the Cas9 "forward sequencing primer 4" nucleic acid sequence.
[0051] SEQ ID NO: 18 is the Cas9 "forward sequencing primer 5" nucleic acid sequence.
[0052] SEQ ID NO: 19 is the Cas9 "forward sequencing primer 6" nucleic acid sequence.
[0053] SEQ ID NO: 20 is the Cas9 "forward sequencing primer 7" nucleic acid sequence.
[0054] SEQ ID NO:21 is the synthetic pRF694 nucleic acid sequence.
[0055] SEQ ID NO:22 is the synthetic pRF748 nucleic acid sequence.
[0056] SEQ ID NO:23 is a synthetic double terminator nucleic acid sequence.
[0057] SEQ ID NO: 24 is the E. coli rpsL promoter (nucleic acid) sequence.
[0058] SEQ ID NO:25 is a synthetic nucleic acid sequence encoding the Cas9 endonuclease recognition domain.
[0059] SEQ ID NO: 26 is the λ phage t0 terminator nucleic acid sequence.
[0060] SEQ ID NO: 27 is the Bacillus subtilis yhfN gene.
[0061] SEQ ID NO:28 is the Bacillus subtilis yhfN target site.
[0062] SEQ ID NO:29 is a synthetic nucleic acid encoding the yhfN VT domain.
[0063] SEQ ID NO: 30 is the Bacillus subtilis yhfN target site PAM sequence.
[0064] SEQ ID NO:31 is the synthetic yhfN guide RNA (gRNA) sequence.
[0065] SEQ ID NO:32 is a synthetic polynucleotide sequence (DNA) encoding yhfN gRNA.
[0066] SEQ ID NO:33 is a synthetic yhfN gRNA polynucleotide (DNA) expression cassette.
[0067] SEQ ID NO:34 is the synthetic pRF793 nucleic acid sequence.
[0068] SEQ ID NO: 35 is a polynucleotide sequence comprising the Bacillus subtilis yhfN locus.
[0069] SEQ ID NO:36 is the synthetic pRF748 forward primer sequence.
[0070] SEQ ID NO: 37 is the synthetic pRF748 reverse primer sequence.
[0071] SEQ ID NO: 38 is the Bacillus subtilis nucleic acid (sequence) of the 5' flanking region of the yhfN locus.
[0072] SEQ ID NO: 39 is the native Bacillus subtilis rrnIp2 promoter nucleic acid sequence.
[0073] SEQ ID NO:40 is the synthetic rrnIp2-1 promoter nucleic acid sequence.
[0074] SEQ ID NO:41 is the synthetic Bacillus amyloliquefaciens apr terminator sequence.
[0075] SEQ ID NO:42 is the Bacillus subtilis nucleic acid (sequence) of the 3' flanking region of the yhfN locus.
[0076] SEQ ID NO:43 is the Bacillus subtilis comK gene.
[0077] SEQ ID NO:44 is the synthetic rrnIp2_α-amylase cassette.
[0078] SEQ ID NO:45 is the synthetic rrnIp2-1_α-amylase cassette.
[0079] SEQ ID NO:46 is the Bacillus licheniformis 5'lysA homology arm.
[0080] SEQ ID NO:47 is a synthetic modified aprE 5'UTR.
[0081] SEQ ID NO:48 is the Bacillus licheniformis lat signal sequence.
[0082] SEQ ID NO:49 is a synthetic DNA sequence encoding a variant Cytophaga sp. alpha-amylase.
[0083] SEQ ID NO:50 is the Bacillus licheniformis lat terminator sequence.
[0084] SEQ ID NO:51 is the Bacillus licheniformis 3'lysA homology arm.
[0085] SEQ ID NO:52 is a synthetic lysA forward primer.
[0086] SEQ ID NO:53 is a synthetic lysA reverse primer.
[0087] SEQ ID NO:54 is synthetic DNA 1032.
[0088] SEQ ID NO:55 is synthetic DNA 1033.
[0089] SEQ ID NO:56 is synthetic DNA 1034.
[0090] SEQ ID NO:57 is synthetic DNA 1035.
[0091] SEQ ID NO:58 is the synthetic rrnIp2-2 promoter sequence.
[0092] SEQ ID NO:59 is the synthetic rrnIp2-3 promoter sequence.
[0093] SEQ ID NO:60 is the complementary sequence of the native rrnIp2 promoter sequence (SEQ ID NO:39).
[0094] SEQ ID NO:61 is the complementary sequence of the synthetic rrnIp2-1 promoter sequence (SEQ ID NO:40).
[0095] SEQ ID NO:62 is the complementary sequence of the synthetic rrnIp2-2 promoter sequence (SEQ ID NO:58).
[0096] SEQ ID NO:63 is the complementary sequence of the synthetic rrnIp2-3 promoter sequence (SEQ ID NO:59).
[0097] SEQ ID NO:64 is the native Bacillus licheniformis amyL promoter region designated herein as PamyL-1, which comprises the native Bacillus licheniformis amyL promoter sequence (SEQ ID NO:82) and the native Bacillus licheniformis amyL 5'-UTR sequence (SEQ ID NO:84).
[0098] SEQ ID NO:65 is a synthetic amyL promoter region designated herein as PamyL-2, which comprises a synthetic amyL promoter sequence (SEQ ID NO:83) operably linked to a native Bacillus licheniformis amyL 5'-UTR sequence (SEQ ID NO:84).
[0099] SEQ ID NO:66 is a synthetic amyL promoter region designated herein as PamyL-3, which comprises the native Bacillus licheniformis amyL promoter sequence (SEQ ID NO:82) operably linked to the native Bacillus subtilis aprE 5'-UTR sequence (SEQ ID NO:85).
[0100] SEQ ID NO:67 is a synthetic amyL promoter region designated herein as PamyL-4, which comprises a synthetic amyL promoter sequence (SEQ ID NO:83) operably linked to a native Bacillus subtilis aprE 5'-UTR sequence (SEQ ID NO:85).
[0101] SEQ ID NO: 68 is the native DNA sequence encoding the mature and truncated B. deramificans pullulanase.
[0102] SEQ ID NO:69 is the synthetic primer sequence.
[0103] SEQ ID NO: 70 is the synthetic primer sequence.
[0104] SEQ ID NO:71 is the synthetic primer sequence.
[0105] SEQ ID NO:72 is the synthetic primer sequence.
[0106] SEQ ID NO:73 is the synthetic primer sequence.
[0107] SEQ ID NO:74 is the synthetic primer sequence.
[0108] SEQ ID NO:75 is the synthetic primer sequence.
[0109] SEQ ID NO:76 is the synthetic primer sequence.
[0110] SEQ ID NO: 77 is the synthetic primer sequence.
[0111] SEQ ID NO:78 is the PamyL-1_pullulanase expression cassette.
[0112] SEQ ID NO:79 is the PamyL-2_pullulanase expression cassette.
[0113] SEQ ID NO:80 is the PamyL-3_pullulanase expression cassette.
[0114] SEQ ID NO:81 is the PamyL-4_pullulanase expression cassette.
[0115] SEQ ID NO: 82 is the native Bacillus licheniformis amyL promoter sequence.
[0116] SEQ ID NO:83 is the synthetic amyL promoter sequence.
[0117] SEQ ID NO: 84 is the native Bacillus licheniformis amyL 5'-UTR sequence.
[0118] SEQ ID NO: 85 is the native Bacillus subtilis aprE 5'-UTR sequence. DETAILED DESCRIPTION
[0119] The present disclosure generally relates to compositions and methods for constructing / producing Bacillus sp. (host) cells (e.g., protein-producing host cells, cell factories) with enhanced protein productivity phenotypes, etc. More particularly, certain embodiments of the present disclosure relate to novel promoter (nucleic acid) sequences, novel expression constructs thereof, modified Bacillus (progeny) cells, etc.
[0120] Therefore, certain embodiments of the present disclosure relate to modified (or mutated) Bacillus species cells. Other embodiments relate to modified Bacillus species cells, which cells comprise one or more novel promoter (nucleic acid) sequences introduced therein (e.g., "modified" or "synthetic" promoter sequences). In other embodiments, one or more promoter sequences are effectively connected to a gene or open reading frame encoding a protein of interest. In other embodiments, the modified Bacillus species (daughter) cells of the present disclosure comprise an enhanced protein productivity phenotype relative to the (parent) Bacillus species cells from which they are derived. Certain other embodiments relate to parent Bacillus species cells comprising endogenous (natural) promoter (nucleic acid) sequences, wherein the modified Bacillus progeny cells derived therefrom comprise their modified (non-natural) promoter sequences.
[0121] I. Definitions
[0122] In view of the modified cells that produce one or more heterologous and / or endogenous proteins of interest and methods thereof described herein, the following terms and phrases are defined. Terms not defined herein shall be given their ordinary meaning as used in the art.
[0123] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those of ordinary skill in the art to which the present invention's compositions and methods belong. Although any methods and materials similar to or equivalent to those described herein may also be used in the practice or testing of the present invention's compositions and methods, representative example methods and materials will now be described. All disclosures and patents cited herein are incorporated by reference in their entirety.
[0124] It is also noted that the claims may be drafted to exclude any optional element. Therefore, this statement is intended to serve as a prerequisite (or condition) for the use of exclusive terminology such as "solely," "only," "exclusively," "not including," etc. in connection with the recitation of claim elements, or the use of a "negative" limitation.
[0125] As will be apparent to those skilled in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features that can be readily separated or combined with the features of any of the other several embodiments without departing from the scope or spirit of the inventive compositions and methods described herein. Any recited method may be performed in the order of events recited or in any other order that is logically possible.
[0126] As used herein, "host cell" refers to a cell that has the ability to serve as a host or expression vehicle for a newly introduced DNA sequence. Thus, in certain embodiments of the present disclosure, the host cell is, for example, a Bacillus sp. cell or an E. coli cell.
[0127] As defined herein, "parent cell" or "parent (host) cell" are used interchangeably and refer to an "unmodified" cell.
[0128] As used herein, "modified cell", "modified (host) cell" are used interchangeably and refer to a recombinant (host) cell that comprises at least one genetic modification that is not present in the "parent" host cell from which the modified cell is derived.
[0129] In certain embodiments, the parental (unmodified) cell may be referred to as a "control cell," particularly when compared to or relative to a modified progeny cell.
[0130] As used herein, when the expression and / or production of a protein of interest (POI) in a parent (unmodified) cell (e.g., a control cell) is compared to the expression and / or production of the same POI in a modified (daughter) cell, it is understood that the "modified" and "unmodified" cells are grown / cultured / fermented under the same conditions (e.g., the same conditions such as culture medium, temperature, pH, etc.).
[0131] As used herein, "Bacillus" or "Bacillus species" cells include all species within the genus "Bacillus" as known to those of skill in the art, including, but not limited to: Bacillus subtilis, Bacillus licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. halodurans, B. megaterium, B. coagulans, B. circulans, B. lautus, and B. thuringiensis. It will be recognized that the genus Bacillus is continually undergoing taxonomic reorganization. Thus, the genus is intended to include species that have been reclassified, including, but not limited to, organisms such as Bacillus stearothermophilus (now designated "Geobacillus stearothermophilus").
[0132] As used herein, the terms "wild-type" and "native" are used interchangeably and refer to a gene, promoter, protein, protein mixture, cell or strain as found in nature.
[0133] As used herein, the term "promoter" generally refers to a nucleic acid sequence that can control the transcription of a coding sequence (or functional RNA). Typically, the coding sequence is located downstream (3') of the promoter sequence. Promoters may all be derived from natural genes, or may be composed of different elements derived from different promoters found in nature, or may even comprise synthetic nucleic acid segments. It will be appreciated by those skilled in the art that different promoters may direct gene expression in different cell types, or at different developmental stages, or in response to different environmental conditions or physiological conditions and the different levels of RNA transcripts produced. Promoters that cause genes to be expressed at similar levels in most cell types in most cases are generally referred to as "constitutive promoters". It is further recognized that, since the exact boundaries of regulatory sequences cannot be fully determined in most cases, DNA fragments of different lengths may have the same promoter activity.
[0134] As used herein, terms such as "functional promoter" and "promoter function" refer in particular to a nucleic acid sequence that is capable of controlling the transcription of a coding sequence (or a functional RNA) when placed upstream of a coding sequence (5') and effectively combined with the coding sequence. For example, the evaluation, estimation, testing, measurement, etc. of promoter function can be easily performed by promoter function / promoter activity assays known to those skilled in the art.
[0135] As used herein, the term "promoter activity" refers to a qualitative or quantitative estimate of promoter function. For example, the promoter activity of an unknown (candidate / test) promoter (nucleic acid) sequence can be assessed and compared with the promoter activity of a known (control) promoter sequence (e.g., using one or more promoter activity assays generally known in the art). Therefore, such promoter activity measurements / assays can be used to understand expression rates, temporal expression, spatial expression, etc. The method of testing / measuring promoter activity is generally based on the expression of a reporter gene (e.g., green fluorescent protein (GFP)), wherein the target promoter sequence is placed upstream (5') of the reporter gene (e.g., GFP) and effectively connected to the reporter gene (e.g., GFP). For example, the target promoter sequence (or its multiple variants, e.g., comprising one or more mutations, deletions, substitutions) can be tested by effectively connecting the target promoter sequence to the upstream (5') of a reporter gene (e.g., GFP) and detecting / measuring changes in the reporter gene. Therefore, fluorescent reporter genes (such as GFP, RFP, etc.) allow those skilled in the art to measure promoter activity, for example, by detecting changes in fluorescent signals (Solberg and Krauss, 2013).
[0136] In certain embodiments of the present disclosure, promoter function (or activity) is assessed by introducing expression cassette (construct) into suitable host cell (for example, Bacillus species cell). For example, in certain embodiments, suitable host cell comprises (a) candidate (test) expression cassette or (b) control expression cassette. More particularly, (a) candidate (test) expression cassette comprises the upstream (5 ') of the open reading frame (ORF) encoding target protein (for example, enzyme) and is effectively connected to the candidate (test) promoter sequence of the open reading frame (ORF) encoding target protein (for example, enzyme), and (b) control cassette comprises the upstream (5 ') of the open reading frame (ORF) encoding the same target protein (for example, same enzyme) and is effectively connected to the control promoter sequence of the open reading frame (ORF) encoding the same target protein (for example, same enzyme). Therefore, the control promoter sequence selected for direct comparison with candidate (test) promoter sequence can be any promoter sequence with known function or activity. In certain embodiments, the control promoter sequence comprises the nucleotide sequence of SEQ ID NO:39. For example, in certain embodiments, a suitable host cell of the present disclosure comprises (a) an introduced "control" expression cassette or (b) an introduced "candidate" (test) expression cassette, wherein the two host cells are subsequently cultured (i.e., under the same conditions), and the amount of the protein of interest expressed / produced between the two host cells (i.e., candidate cells and control cells) is directly compared.
[0137] As used herein, the “native Bacillus sp. rrnIp2 promoter” (hereinafter referred to as “rrnIp2” promoter) comprises the nucleotide sequence shown in SEQ ID NO:39.
[0138] As used herein, phrases such as "modified rrnIp2" promoter, "synthetic rrnIp2" promoter, "variant rrnIp2" promoter, "mutated rrnIp2" promoter, "mutant rrnIp2" promoter, etc. refer to a genetically modified promoter sequence derived from the "native rrnIp2" promoter of SEQ ID NO: 39. For example, in certain embodiments, the modified (non-native) rrnIp2 promoter of the present disclosure comprises at least one modified nucleotide position with reference to the native rrnIp2 promoter (positions 1-91) of SEQ ID NO: 39, wherein the at least one (1) modified nucleotide position is selected from position 1, 89, 90, or 91 of SEQ ID NO: 39.
[0139] In other embodiments, the modified (non-native) rrnIp2 promoter of the present disclosure comprises at least two (2) modified nucleotide positions with reference to the native rrnIp2 promoter (positions 1-91) of SEQ ID NO:39, wherein the at least two modified nucleotide positions are selected from position 1, 89, 90, or 91 of SEQ ID NO:39.
[0140] In other embodiments, the modified (non-native) rrnIp2 promoter of the present disclosure comprises at least three (3) modified nucleotide positions with reference to the native rrnIp2 promoter (positions 1-91) of SEQ ID NO:39, wherein the at least three modified nucleotide positions are selected from positions 1, 89, 90, or 91 of SEQ ID NO:39.
[0141] In other embodiments, the modified (non-native) rrnIp2 promoter of the present disclosure comprises at least four (4) modified nucleotide positions with reference to the native rrnIp2 promoter (positions 1-91) of SEQ ID NO:39, wherein the at least four modified nucleotide positions are 1, 89, 90, and 91 of SEQ ID NO:39.
[0142] As used herein, the "rrnIp2-1" promoter comprises at least 90% sequence identity to SEQ ID NO: 40 and comprises a thymine (T) at nucleotide position 30, a thymine (T) at nucleotide position 89, a guanine (G) at nucleotide position 90, and a thymine (T) at nucleotide position 91 of SEQ ID NO: 40. In certain other embodiments, the "rrnIp2-1" promoter comprises at least 90% to about 99% sequence identity to SEQ ID NO: 40 and comprises a thymine (T) at nucleotide position 30, a thymine (T) at nucleotide position 89, a guanine (G) at nucleotide position 90, and a thymine (T) at nucleotide position 91 of SEQ ID NO: 40.
[0143] As used herein, the "rrnIp2-2" promoter comprises at least 90% sequence identity to SEQ ID NO: 58 and comprises a T at nucleotide position 89, a G at nucleotide position 90, and a T at nucleotide position 91 of SEQ ID NO: 58. In certain other embodiments, the "rrnIp2-2" promoter comprises at least 90% to about 99% sequence identity to SEQ ID NO: 58 and comprises a T at nucleotide position 89, a G at nucleotide position 90, and a T at nucleotide position 91 of SEQ ID NO: 58.
[0144] As used herein, the "rrnIp2-3" promoter comprises at least 90% sequence identity to SEQ ID NO:59 and comprises a T at nucleotide position 30 of SEQ ID NO:59. In certain other embodiments, the "rrnIp2-3" promoter comprises at least 90% to about 99% sequence identity to SEQ ID NO:59.
[0145] As used herein, terms such as "synthetic" rrnIp2-1 promoter, "synthetic" rrnIp2-2 promoter, "synthetic" rrnIp2-3 promoter, "modified" rrnIp2-1 promoter, "modified" rrnIp2-2 promoter, "modified" rrnIp2-3 promoter, etc. refer to one or more (non-native) rrnIp2 promoter sequences (i.e., compared to the native rrnIp2 promoter sequence (SEQ ID NO: 39)).
[0146] Therefore, in certain embodiments, when operably linked to a gene or ORF encoding a protein of interest, the synthetic, variant or modified rrnIp2 promoter of the present disclosure (e.g., rrnIp2-1, rrnIp2-2, rrnIp2-3) comprises an enhanced promoter function or activity (e.g., an enhanced protein productivity phenotype). In certain related embodiments, relative to the native rrnIp2 promoter sequence of SEQ ID NO: 39, the synthetic, variant or modified rrnIp2 promoter of the present disclosure comprises an enhanced promoter function or activity.
[0147] Thus, in certain other embodiments, a parent Bacillus sp. cell comprising an endogenous native rrnIp2 promoter is modified according to the methods of the present disclosure, wherein the modified Bacillus sp. (progeny) cell derived therefrom comprises a mutant (non-native) rrnIp2 promoter of the present disclosure.
[0148] As used herein, with respect to a native rrnIp2 promoter or a variant (modified) rrnIp2 promoter derived therefrom (e.g., rrnIp2-1, rrnIp2-2, rrnIp2-3), the "positions" of nucleotides in a given "nucleic acid sequence" (i.e., the rrnIp2 promoter sequence disclosed herein) are numbered by reference to the native Bacillus subtilis rrnIp2 promoter of SEQ ID NO:39 (read in the 5' to 3' direction), which promoter sequence comprises nucleotides 1-91 (e.g., Figure 1 A- Figure 1 C).
[0149] For example, Figure 1 A- Figure 1 C, the candidate (test) promoter (nucleic acid) sequence described herein can be aligned with the native Bacillus subtilis rrnIp2 promoter sequence (SEQ ID NO:39; nucleotide positions 1-91) using the alignment algorithm described herein and / or an alignment algorithm known in the related art, wherein the nucleotide positions in the candidate (test) sequence aligned with the native promoter sequence of SEQ ID NO:39 can be numbered by reference to the corresponding one or more nucleotide positions in the native sequence. For example, Figure 1As presented in Figure 4A, the novel (synthetic) rrnIp2-1 promoter sequence of the present disclosure (i.e., SEQ ID NO:40) is aligned with the native Bacillus sp. rrnIp2 promoter sequence (i.e., SEQ ID NO:39), wherein there are four (4) nucleotide differences between the native rrnIp2 promoter (SEQ ID NO:39) and the novel rrnIp2-1 promoter (SEQ ID NO:40) at positions 30, 89, 90, and 91. Therefore, in order to establish sequence homology (or identity) with the native rrnIp2 promoter sequence of SEQ ID NO:39, one skilled in the art can easily compare the native rrnIp2 promoter sequence with one or more candidate (test) promoter sequences of interest using sequence alignment algorithms, software, and methods thereof known to those skilled in the art.
[0150] In certain embodiments, the novel variant rrnIp2 promoter comprises a nucleic acid sequence that hybridizes to the native rrnIp2 promoter sequence of SEQ ID NO: 39 or its complementary sequence SEQ ID NO: 60 (under stringent hybridization conditions). For example, in certain embodiments, the novel variant rrnIp2 promoter comprises a nucleic acid sequence that hybridizes to the complementary rrnIp2 promoter sequence comprising SEQ ID NO: 60 (under stringent hybridization conditions), wherein the hybridizing variant sequence comprises at least one nucleotide substitution at a position selected from 30, 89, 90, or 91 (relative to the same position of the native rrnIp2 promoter sequence of SEQ ID NO: 39). Thus, in other embodiments, the novel variant rrnIp2 promoter sequence of the present disclosure that hybridizes (under stringent hybridization conditions) comprises a T at nucleotide position 89, a G at nucleotide position 90, and a T at nucleotide position 91 (i.e., relative to SEQ ID NO: 39 comprising A, A, A at nucleotide positions 89-91). In other embodiments, the novel variant rrnIp2 promoter that hybridizes (under stringent hybridization conditions) comprises SEQ ID NO:40, 58, or 59.
[0151] As used herein, the native Bacillus licheniformis “amyL promoter region” hereinafter referred to as “PamyL-1” comprises the nucleotide sequence shown in SEQ ID NO:64.
[0152] As used herein, the modified (synthetic) “amyL promoter region” hereinafter referred to as “PamyL-2” comprises the nucleotide sequence shown in SEQ ID NO:65.
[0153] In certain embodiments, the modified (synthetic) PamyL-2 sequence comprises at least 90% to about 99% sequence identity to SEQ ID NO:64 and comprises a thymine (T) at nucleotide position 72 of SEQ ID NO:64, a guanine (G) at nucleotide position 73 of SEQ ID NO:64, and a thymine (T) at nucleotide position 74 of SEQ ID NO:64.
[0154] As used herein, with respect to native PamyL-1 sequences and modified (synthetic) PamyL-2 sequences, the "positions" of nucleotides in a given "nucleic acid sequence" are numbered by reference to the native Bacillus licheniformis amyL promoter region PamyL-1 of SEQ ID NO:64 (reading in the 5' to 3' direction), wherein the native PamyL-1 promoter region sequence comprises nucleotide positions 1-100 (i.e., 5' to 3', e.g., 5' to 3') of SEQ ID NO:64. Figure 3 presented).
[0155] For example, Figure 3 As shown, the native PamyL-1 promoter region comprises a native amyL promoter sequence and a native amyL 5′-UTR sequence, wherein the native amyL promoter sequence comprises nucleotide positions 1-74 of SEQ ID NO:64, and the native amyL 5′-UTR sequence comprises nucleotide positions 75-100 of SEQ ID NO:64; and the modified (synthetic) PamyL-2 promoter region comprises a modified amyL promoter sequence operably linked to the native amyL 5′-UTR sequence, wherein the modified amyL promoter sequence comprises nucleotide positions 1-74 of SEQ ID NO:65, and the native amyL 5′-UTR sequence comprises nucleotide positions 75-100 of SEQ ID NO:65.
[0156] As used herein, the native Bacillus licheniformis "amyL promoter" sequence comprises the nucleotide sequence shown in SEQ ID NO:82.
[0157] As used herein, a modified (synthetic) "amyL promoter" sequence comprises the nucleotide sequence set forth in SEQ ID NO: 83 and comprises a thymine (T) at nucleotide position 72 of SEQ ID NO: 83, a guanine (G) at nucleotide position 73 of SEQ ID NO: 83, and a thymine (T) at nucleotide position 74 of SEQ ID NO: 83. In certain embodiments, a modified (synthetic) amyL promoter sequence comprises a nucleotide sequence comprising at least 90% to about 99% sequence identity to SEQ ID NO: 82 and comprising a thymine (T) at nucleotide position 72 of SEQ ID NO: 82, a guanine (G) at nucleotide position 73 of SEQ ID NO: 82, and a thymine (T) at nucleotide position 74 of SEQ ID NO: 82.
[0158] As used herein, with respect to native Bacillus licheniformis amyL promoter sequences and modified amyL promoter sequences, the "positions" of nucleotides in a given "nucleic acid sequence" are numbered by reference to the native Bacillus licheniformis amyL promoter sequence of SEQ ID NO:82 (reading in the 5' to 3' direction), which comprises nucleotide positions 1-74 of SEQ ID NO:82 (i.e., 5' to 3', e.g., Figure 4 For example, Figure 4 As shown, the native amyL promoter sequence (SEQ ID NO: 82) comprises nucleotides A, T, and G at 72, 73, and 74, respectively, and the modified amyL promoter sequence (SEQ ID NO: 83) comprises nucleotides T, G, and T at nucleotide positions 72, 73, and 74, respectively.
[0159] As used herein, the native Bacillus licheniformis "amyL 5'-UTR" sequence comprises the nucleotide sequence shown in SEQ ID NO:84.
[0160] As used herein, the native Bacillus subtilis “aprE 5′-UTR” comprises the nucleotide sequence shown in SEQ ID NO:85.
[0161] As used herein, the modified (synthetic) “amyL promoter region” hereinafter referred to as “PamyL-3” comprises the nucleotide sequence shown in SEQ ID NO:66.
[0162] As used herein, the modified (synthetic) “amyL promoter region” hereinafter referred to as “PamyL-4” comprises the nucleotide sequence shown in SEQ ID NO:67.
[0163] In certain embodiments, the modified (synthetic) PamyL-4 sequence comprises at least 90% to about 99% sequence identity to SEQ ID NO:66 and comprises a thymine (T) at nucleotide position 72 of SEQ ID NO:66, a guanine (G) at nucleotide position 73 of SEQ ID NO:66, and a thymine (T) at nucleotide position 74 of SEQ ID NO:66.
[0164] Thus, as used herein, with respect to the synthetic PamyL-3 promoter region and the synthetic PamyL-4 promoter region, the "positions" of nucleotides in a given "nucleic acid sequence" are numbered by reference to the synthetic PamyL-3 promoter region of SEQ ID NO:66 (reading in the 5' to 3' direction), wherein the PamyL-3 promoter region sequence comprises nucleotide positions 1-132 of SEQ ID NO:66 (i.e., 5' to 3', e.g., Figure 5 presented).
[0165] For example, Figure 5 As shown, the synthetic PamyL-3 promoter region (SEQ ID NO:66) comprises a native amyL promoter sequence (e.g., SEQ ID NO:82) operably linked to a native Bacillus subtilis aprE 5′-UTR sequence (e.g., SEQ ID NO:85), the native amyL promoter sequence comprising nucleotide positions 1-74 of SEQ ID NO:66, and the native Bacillus subtilis aprE 5′-UTR sequence comprising nucleotide positions 75-132 of SEQ ID NO:66. Similarly, Figure 5 As presented, the synthetic PamyL-4 promoter region (SEQ ID NO:67) comprises a modified amyL promoter sequence (e.g., SEQ ID NO:83) operably linked to a native Bacillus subtilis aprE 5′-UTR sequence (e.g., SEQ ID NO:85), wherein the modified amyL promoter sequence comprises nucleotide positions 1-74 of SEQ ID NO:67, and the native Bacillus subtilis aprE 5′-UTR sequence comprises nucleotide positions 75-132 of SEQ ID NO:67.
[0166] Therefore, if Figure 5 As shown, the PamyL-3 promoter region (SEQ ID NO:66) comprises nucleotides A, T, and G at nucleotide positions 72, 73, and 74, respectively, and the PamyL-4 promoter region (SEQ ID NO:67) comprises nucleotides T, G, and T at nucleotide positions 72, 73, and 74, respectively.
[0167] As used herein, with respect to the PamyL-1 promoter region (SEQ ID NO:64), the PamyL-2 promoter region (SEQ ID NO:65), the PamyL-3 promoter region (SEQ ID NO:66), and the PamyL-4 promoter region (SEQ ID NO:67), the term "promoter region" or "promoter region sequence" refers to a nucleic acid sequence comprising at least one upstream (5') promoter sequence operably linked to a downstream (3') 5-UTR sequence.
[0168] As used herein, "nucleic acid" refers to nucleotide or polynucleotide sequences and fragments or portions thereof, as well as DNA, cDNA and RNA of genomic or synthetic origin, which may be double-stranded or single-stranded, whether representing the sense or antisense strand.
[0169] As used herein, the term "3'-untranslated region" is abbreviated as "3'-UTR", and the term "5'-untranslated region" is abbreviated as "5'-UTR".
[0170] As used herein, the term "effectively connected" refers to the association of nucleic acid sequences on a single nucleic acid fragment, so that the function of one nucleic acid fragment is affected by another. For example, when the transcription of the coding sequence can be achieved (i.e., the coding sequence is under the transcriptional control of the promoter), the promoter is effectively connected to the coding sequence (e.g., ORF). The coding sequence can be effectively connected to the regulatory sequence in the sense or antisense direction. When a nucleic acid is placed in a functional relationship with another nucleic acid sequence, the nucleic acid is "effectively connected" to another nucleic acid sequence. For example, if the DNA encoding the secretory leader (i.e., signal peptide) is expressed as a preprotein participating in the secretion of a polypeptide, the DNA encoding the secretory leader is effectively connected to the DNA of the polypeptide; if the promoter or enhancer affects the transcription of the coding sequence, the promoter or enhancer is effectively connected to the sequence; or if the ribosome binding site is positioned to promote translation, the ribosome binding site is effectively connected to the coding sequence. Generally, "effectively connected" means that the DNA sequence being connected is continuous, and in the case of a secretory leader, it is continuous and in the reading phase. However, enhancers do not have to be continuous. Linking is accomplished by ligation at convenient restriction sites or by seamless assembly methods. If such sites do not exist, synthetic oligonucleotide adapters or linkers are used in accordance with conventional practice.
[0171] As used herein, "suitable regulatory sequence" refers to a nucleotide sequence that is located upstream (5' non-coding sequence), internal or downstream (3' non-coding sequence) of a coding sequence and affects transcription, RNA processing or stability or translation of the relevant coding sequence. Regulatory sequences can include promoters, translation leader sequences, one or more RNA processing sites, one or more effector binding sites, stem-loop structures, and other RNA stability motifs.
[0172] As used herein, the term "expression" refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid molecules of the present disclosure. Expression may also refer to the translation of mRNA into polypeptides. Therefore, the term "expression" includes any step involved in the production of polypeptides, including but not limited to transcription, post-transcriptional modification, translation, post-translational modification, secretion, etc.
[0173] As used herein, the combined terms "expression / production", as used in phrases such as "the Bacillus sp. (progeny) cells express / produce 'increased' amounts of a protein of interest (POI)" (i.e., relative to the parental cells), are intended to include any steps involved in the expression and production of a protein in such Bacillus sp. (progeny) cells of the present disclosure.
[0174] As used herein, the terms "increased expression", "enhanced expression", "increased POI expression", "increased production", "increased POI production" and the like refer to "modified" Bacillus (progeny) cells, wherein "increase" is always relative (compared) to an "unmodified" Bacillus (parent) cell expressing / producing the same POI.
[0175] Likewise, as used herein, when used in phrases such as "the modified host cell 'expresses / produces' an increased amount of one or more proteins of interest relative to the (unmodified) parent host cell", "increased amount" refers specifically to any "increased amount" of a protein of interest (POI) expressed / produced in a modified host cell, the "increased amount" being always relative to the (unmodified) parent Bacillus cell expressing / producing the same POI, wherein the modified and unmodified cells are grown / cultured / fermented under the same conditions (e.g., the same conditions such as culture medium, temperature, pH, etc.). For example, the increased amount of the POI may be an endogenous POI or a heterologous POI expressed in the modified Bacillus cell of the present disclosure.
[0176] Therefore, as used herein, "increase" protein production or "increased" protein production means that the amount of the protein (e.g., target protein) produced increases. The protein can be produced in the host cell, or secreted (or transported) into the culture medium. In certain embodiments, the target protein is produced (secreted) into the culture medium. As compared with the parent host cell, the increased protein production can be detected as a higher maximum level of, for example, protein or enzyme activity (e.g., such as protease activity, amylase activity, cellulase activity, hemicellulase activity, etc.) or total extracellular protein produced.
[0177] As used herein, modified cells comprising an "enhanced protein productivity phenotype" include, but are not limited to, modified cells comprising enhanced / increased volumetric productivity, modified cells comprising enhanced / increased carbon conversion efficiency, modified cells comprising enhanced / increased protein yield, modified cells comprising enhanced / increased specific protein productivity, etc.
[0178] As used herein, the phrases "enhanced protein productivity phenotype" and "increased protein productivity phenotype" are used interchangeably.
[0179] As used herein, when describing an "enhanced / increased protein productivity phenotype" of an unmodified (parent) cell versus a modified (variant / progeny) cell, it is understood that the "parent" and "variant" cells are grown / cultured / fermented under the same conditions (e.g., the same conditions such as culture medium, temperature, pH, etc.). \
[0180] As used herein, the term "introduced", as used in phrases such as "introducing into a cell" at least one polynucleotide open reading frame (ORF) or its gene or its vector, includes methods known in the art for introducing a polynucleotide into a cell, including but not limited to protoplast fusion, natural or artificial transformation (e.g., calcium chloride, electroporation), transduction, transfection, and the like.
[0181] It should be understood that the polynucleotides (or nucleic acid molecules) described herein include "genes", "vectors" and "plasmids".
[0182] Therefore, the term "gene" refers to a polynucleotide encoding a specific sequence of amino acids, which comprises all or part of a protein coding sequence, and may include a regulatory (non-transcribed) DNA sequence, such as a promoter sequence, which determines, for example, the conditions under which a gene is expressed. The transcribed region of a gene may include an untranslated region (UTR) (the untranslated region includes introns, 5'-untranslated region (UTR) and 3'-UTR), and a coding sequence.
[0183] As used herein, the term "coding sequence" refers to a nucleotide sequence that directly determines the amino acid sequence of its (encoded) protein product. The boundaries of a coding sequence are generally determined by an open reading frame (hereinafter referred to as "ORF") that usually begins with the ATG start codon. Coding sequences generally include DNA, cDNA, and recombinant nucleotide sequences.
[0184] As defined herein, the term "open reading frame" (hereinafter referred to as "ORF") means a nucleic acid or nucleic acid sequence (whether naturally occurring, non-naturally occurring, or synthetic) that comprises an uninterrupted reading frame consisting of: (i) a start codon, (ii) a series of two (2) or more codons representing amino acids, and (iii) a stop codon, the ORF being read (or translated) in the 5' to 3' direction.
[0185] As defined herein, "suitable regulatory sequences" refer to nucleotide sequences that are located upstream (5' non-coding sequences), internal or downstream (3' non-coding sequences) of a coding sequence and that affect transcription, RNA processing or stability or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, RNA processing sites, effector binding sites, and stem-loop structures.
[0186] As defined herein, the term "introduced", as used in phrases such as "introducing into a bacterial cell" or "introducing into a Bacillus cell" at least one polynucleotide open reading frame (ORF) or a gene thereof or a vector thereof, includes methods known in the art for introducing a polynucleotide into a cell, including but not limited to protoplast fusion, natural or artificial transformation (e.g., calcium chloride, electroporation), transduction, transfection, conjugation, etc. (e.g., see Ferrari et al., 1989).
[0187] As used herein, "converted" or "conversion" means a cell transformed by using recombinant DNA technology. Conversion usually occurs by inserting one or more nucleotide sequences (e.g., polynucleotides, ORFs or genes) into a cell. The inserted nucleotide sequence can be a heterologous nucleotide sequence (i.e., a sequence that is not naturally occurring in the cell to be transformed). As used herein, "conversion" refers to the introduction of exogenous DNA into a host cell so that DNA remains as a chromosome integrant or a self-replicating extrachromosomal vector. As used herein, "conversion DNA", "conversion sequence" and "DNA construct" refer to the DNA for introducing a sequence into a host cell or an organism. Conversion DNA is a DNA for introducing a sequence into a host cell or an organism. DNA can be produced in vitro by PCR or any other suitable technology. In certain embodiments, conversion DNA comprises an input sequence, and in other embodiments, it also comprises an input sequence flanking a homology box. In another embodiment, conversion DNA comprises other non-homologous sequences, added to the end (i.e., a stuffing sequence or a flank). The end can be closed so that the conversion DNA forms a closed loop, such as, for example, inserted into a vector.
[0188] As used herein, "input sequence" refers to the DNA sequence introduced into the Bacillus chromosome. In certain embodiments, the input sequence is a part for a DNA construct. In other embodiments, the input sequence encodes one or more target proteins. In certain embodiments, the input sequence comprises a sequence that may or may not be present in the genome of the cell to be transformed (that is, it may be a homologous or heterologous sequence). In certain embodiments, the input sequence encodes one or more target proteins, genes, and / or mutants or modified genes. In alternative embodiments, the input sequence encodes functional wild-type genes or operons, genes or operons of functional mutations or non-functional genes or operons. In certain embodiments, non-functional sequences can be inserted into genes to destroy the function of genes. In another embodiment, the input sequence includes a selective marker. In another embodiment, the input sequence includes two homology boxes (for example, upstream and downstream homology arms).
[0189] As used herein, "homologous box" refers to a nucleic acid sequence homologous to a sequence in a Bacillus chromosome. More specifically, according to the present invention, a homologous box is an upstream or downstream region, and the upstream or downstream region has a sequence identity between about 80% and 100%, a sequence identity between about 90% and 100%, or a sequence identity between about 95% and 100% with the tight flanking region of the target chromosome locus. These sequences guide the integration position of the DNA construct in the Bacillus chromosome, and guide which part of the Bacillus chromosome (if any) is replaced by the input sequence. Although it is not intended to limit the present disclosure, the homologous box can include about 1 base pair (bp) to 200 kilobases (kb). Preferably, the homologous box includes about 1bp and 10.0kb, 1bp and 5.0kb, 1bp and 2.5kb, 1bp and 1.0kb, and 0.25kb and 2.5kb. Homology boxes can also include about 10.0 kb, 5.0 kb, 2.5 kb, 2.0 kb, 1.5 kb, 1.0 kb, 0.5 kb, 0.25 kb and 0.1 kb. In some embodiments, the 5' and 3' ends of the selectable marker are flanked by homology boxes (homology arms), wherein the homology boxes contain nucleic acid sequences that are closely located on the coding region of the gene.
[0190] In still another embodiment of the present disclosure, as determined by DNA array analysis (e.g., transcriptome analysis as described herein), deletion, destruction, inactivation or downregulation of gene activity at inappropriate times provides enhanced expression of a protein of interest. As used herein, "transcriptome analysis" refers to analysis of gene transcription.
[0191] As used herein, the term "nucleotide sequence encoding a selectable marker" refers to a nucleotide sequence that is capable of being expressed in a host cell and wherein expression of the selectable marker confers upon the cells containing the expressed gene the ability to grow in the absence of the corresponding selective agent or in the absence of essential nutrients.
[0192] As used herein, the terms "selectable marker" and "selective marker" refer to a nucleic acid (e.g., a gene) that can be expressed in a host cell that allows easy selection of those hosts that contain the vector. Examples of such selectable markers include, but are not limited to, antimicrobial agents. Thus, the term "selectable marker" refers to a gene that provides an indication that the host cell has taken up the input DNA of interest or that some other reaction has occurred. Typically, a selectable marker is a gene that confers antimicrobial resistance or a metabolic advantage to a host cell to allow cells containing exogenous DNA to be distinguished from cells that have not received any exogenous sequences during transformation.
[0193] A "residing selectable marker" is a marker located on the chromosome of the microorganism to be transformed. The residing selectable marker encodes a gene that is different from the selectable marker on the transforming DNA construct. Selectable markers are well known to those skilled in the art. As described above, the marker can be an antimicrobial resistance marker (e.g., amp R , phleo R 、spec R ,kan R ery R , tet R 、cmp R , and neo R ). In some embodiments, the present invention provides chloramphenicol resistance genes (e.g., genes present on pC194, and resistance genes present in the genome of Bacillus licheniformis). Such resistance genes are particularly useful in the present invention and in embodiments involving chromosomal amplification of cassettes for chromosomal integration and integrated plasmids. Other markers useful according to the present invention include, but are not limited to, auxotrophic markers such as serine, lysine, tryptophan; and detection markers such as β-galactosidase.
[0194] As defined herein, a host cell "genome", a bacterial (host) cell "genome", or a Bacillus (host) cell "genome" includes chromosomal genes and extrachromosomal genes.
[0195] As used herein, the terms "plasmid", "vector" and "cassette" refer to an extrachromosomal element that usually carries genes that are not usually part of the central metabolism of the cell and is usually in the form of a circular double-stranded DNA molecule. Such elements can be linear or circular self-replicating sequences derived from single-stranded or double-stranded DNA or RNA from any source, genome integrating sequences, bacteriophages, or nucleotide sequences in which many nucleotide sequences have been linked or recombined into a single structure that is capable of introducing a promoter fragment and DNA sequence for a selected gene product, along with appropriate 3' untranslated sequences, into a cell.
[0196] As used herein, "transformation cassette" refers to a specific vector that contains a gene (or its ORF) and has elements in addition to the exogenous gene that facilitate transformation of a specific host cell.
[0197] As used herein, the term "vector" refers to any nucleic acid that can replicate (propagate) in a cell and can carry a new gene or DNA segment into a cell. Therefore, the term refers to a nucleic acid construct designed to be transferred between different host cells. Vectors include viruses, phages, proviruses, plasmids, phagemids, transposons, and artificial chromosomes such as YAC (yeast artificial chromosome), BAC (bacterial artificial chromosome), PLAC (plant artificial chromosome), etc. that are "episomes" (i.e., they replicate autonomously or can be integrated into the chromosome of a host organism).
[0198] "Expression vector" refers to a vector that has the ability to incorporate and express heterologous DNA in a cell. Many prokaryotic and eukaryotic expression vectors are commercially available and are well known to those skilled in the art. The selection of an appropriate expression vector is within the knowledge of those skilled in the art.
[0199] As used herein, the terms "expression cassette" and "expression vector" refer to a nucleic acid construct (i.e., these are vectors or vector elements, as described above) that is recombinantly or synthetically produced with a series of specific nucleic acid elements that allow a specific nucleic acid to be transcribed in a target cell. The recombinant expression cassette can be incorporated into a plasmid, a chromosome, a mitochondrial DNA, a plasmid DNA, a virus, or a nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes (in addition to other sequences) a nucleic acid sequence to be transcribed and a promoter. In some embodiments, the DNA construct also includes a series of specific nucleic acid elements that allow transcription of a specific nucleic acid in a target cell. In certain embodiments, the DNA construct of the present disclosure comprises a selective marker as defined herein and an inactivated chromosome or gene or DNA segment.
[0200] As used herein, "targeting vector" is a vector comprising a polynucleotide sequence homologous to a region in the chromosome of a host cell transformed with the targeting vector, and the vector can drive homologous recombination in the region. For example, the targeting vector can be used to introduce a mutation into the host cell chromosome by homologous recombination. In certain embodiments, the targeting vector comprises other non-homologous sequences, such as added to the end (i.e., stuffing sequence or flanking sequence). The end can be closed so that the targeting vector forms a closed loop, such as, inserted into a vector. The selection and / or construction of an appropriate vector are fully within the knowledge of those skilled in the art.
[0201] As used herein, the term "plasmid" refers to a circular double-stranded (ds) DNA construct used as a cloning vector, and which forms an extrachromosomal self-replicating element, a conditional self-replicating element, or a non-replicating genetic element in many bacteria and some eukaryotic organisms. In some embodiments, the plasmid is incorporated into the genome of the host cell.
[0202] As used herein, the term "protein of interest" or "POI" refers to a polypeptide of interest that is desired to be expressed in a modified Bacillus (progeny) cell, wherein the POI is preferably expressed at an enhanced / increased level (i.e., relative to "unmodified" (parent) cells). Thus, as used herein, a POI may be an enzyme, a substrate binding protein, a surfactant protein, a structural protein, a receptor protein, an antibody, etc.
[0203] Similarly, as defined herein, "target gene" or "GOI" refers to a nucleic acid sequence (eg, polynucleotide, gene, or ORF) encoding a POI. A "target gene" encoding a "target protein" may be a naturally occurring gene, a mutant gene, or a synthetic gene.
[0204] In certain embodiments, the modified cells of the present disclosure produce an increased amount of a heterologous POI or an endogenous POI relative to the parent cell. In specific embodiments, the increased amount of POI produced by the modified cells of the present disclosure is an increase of at least 0.05%, an increase of at least 0.10%, an increase of at least 1.0%, an increase of at least 5.0%, or an increase of more than 5.0% relative to the parent cell. As a non-limiting example, in certain embodiments, the POI is an enzyme (e.g., a hydrolase), wherein the increased level of the POI produced by the modified cell (i.e., relative to its unmodified parent) is detected or measured as an increase in enzyme activity and / or an increase in specific productivity (Qp).
[0205] As used herein, the terms "polypeptide" and "protein" are used interchangeably and refer to a polymer of any length comprising amino acid residues linked by peptide bonds. Conventional single (1) letter or three (3) letter codes for amino acid residues are used herein. A polypeptide may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The term polypeptide also encompasses amino acid polymers modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more amino acid analogs (including, for example, non-natural amino acids, etc.), as well as other modifications known in the art.
[0206] In certain embodiments, the genes of the present disclosure encode commercially relevant proteins of industrial interest, such as enzymes (e.g., acetylesterase, aminopeptidase, amylase, arabinase, arabinofuranosidase, carbonic anhydrase, carboxypeptidase, catalase, cellulase, chitinase, chymosin, cutinase, deoxyribonuclease, epimerase, esterase, α-galactosidase, β-galactosidase, α-glucanase, glucan lyase, endo-β-glucanase, glucoamylase, glucose oxidase, α-glucosidase, β-glucosidase, glucose lyases, mannosidases, oxidases, oxidoreductases, pectin lyases, pectin acetylesterases, pectin depolymerases, pectin methylesterases, pectinolytic enzymes, perhydrolases, polyol oxidases, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, peptidases, rhamnogalacturonases, ribonucleases, transferases, transporters, transglutaminases, xylanases, hexose oxidases, and combinations thereof).
[0207] As used herein, a "variant" polypeptide refers to a polypeptide derived from a parent (or reference) polypeptide, usually by recombinant DNA technology, by substitution, addition or deletion of one or more amino acids. Variant polypeptides can differ from parent polypeptides by a small number of amino acid residues and can be defined by their level of primary amino acid sequence homology / identity with the parent (reference) polypeptide.
[0208] Preferably, the variant polypeptide has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or even at least 99% amino acid sequence identity with the parent (reference) polypeptide sequence. As used herein, a "variant" polynucleotide refers to a polynucleotide encoding a variant polypeptide, wherein the "variant polynucleotide" has a certain degree of sequence homology / identity with the parent polynucleotide, or hybridizes with the parent polynucleotide (or its complementary sequence) under stringent hybridization conditions. Preferably, the variant polynucleotide has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or even at least 99% nucleotide sequence identity with the parent (reference) polynucleotide sequence.
[0209] As used herein, "mutation" refers to any change or alteration in a nucleic acid sequence. There are several types of mutations, including point mutations, deletion mutations, silent mutations, frame shift mutations, splicing mutations, etc. Mutations can be made specifically (e.g., via site-directed mutagenesis) or randomly (e.g., via chemical agents, by repair minus bacterial strain passage) or occur spontaneously.
[0210] As used herein, the term "substitution" in the context of a polypeptide or sequence thereof means that one amino acid is replaced (ie, substituted) by another amino acid.
[0211] As defined herein, "endogenous gene" refers to a gene that is located in its natural location in the genome of an organism.
[0212] As defined herein, a "heterologous" gene, "non-endogenous" gene, or "foreign" gene refers to a gene (or ORF) that is not normally found in the host organism, but is introduced into the host organism by gene transfer. As used herein, the term "foreign" gene(s) includes native genes (or ORFs) inserted into non-native organisms and / or chimeric genes inserted into native or non-native organisms.
[0213] As defined herein, a "heterologous" nucleic acid construct or "heterologous" nucleic acid sequence has a portion that is not a native sequence of the cell in which it is expressed.
[0214] As defined herein, "heterologous control sequences" refer to gene expression control sequences (e.g., promoters or enhancers) that do not function to regulate (control) the expression of a gene of interest in nature. Typically, heterologous nucleic acid sequences are not endogenous (natural) to the cell or partial genome in which they are present, and have been added to the cell by infection, transfection, transformation, microinjection, electroporation, etc. A "heterologous" nucleic acid construct may comprise a control sequence / DNA coding (ORF) sequence combination that is identical or different to the control sequence / DNA coding (ORF) sequence combination found in a natural host cell.
[0215] As used herein, the terms "signal sequence" and "signal peptide" refer to a sequence of amino acid residues that can participate in the secretion or directional transport of a mature protein or a precursor form of a protein. Typically, the signal sequence is located at the N-terminus of the precursor or mature protein sequence. The signal sequence can be endogenous or exogenous. A signal sequence is generally not present in a mature protein. Typically, after protein transport, the signal sequence is cut from the protein by a signal peptidase.
[0216] The term "derived" encompasses the terms "originating," "obtained," "obtainable," and "created," and generally indicates that one specified material or composition finds its origin in, or has characteristics that can be described with reference to, another specified material or composition.
[0217] As used herein, the term "homology" relates to homologous polynucleotides or polypeptides. If two or more polynucleotides or two or more polypeptides are homologous, this means that the homologous polynucleotides or polypeptides have at least 60%, more preferably at least 70%, even more preferably at least 85%, still more preferably at least 90%, more preferably at least 95%, and most preferably at least 98% "degree of identity". Whether two polynucleotides or polypeptide sequences have a sufficiently high degree of identity as defined herein, two sequences can be suitably studied by aligning two sequences using a computer program known in the art, such as "GAP" (Program Manual for the Wisconsin Package [Wisconsin Package Manual] provided in the GCG program package, 8th Edition, August 1994, Genetics Computer Group (Genetics Computer Group), 575 Science Drive, Madison, Wisconsin, 53711, U.S.) (Needleman and Wunsch, (1970)). DNA sequence comparisons were performed using GAP with the following settings: GAP creation penalty 5.0 and GAP extension penalty 0.3.
[0218] As used herein, the term "percent (%) identity" refers to the level of nucleic acid or amino acid sequence identity between nucleic acid sequences encoding polypeptides or amino acid sequences of polypeptides when aligned using sequence alignment programs.
[0219] As used herein, "specific productivity" is the total amount of protein produced per cell per time in a given period of time.
[0220] As defined herein, the terms "purified," "isolated," or "enriched" mean that a biomolecule (e.g., a polypeptide or polynucleotide) is altered from its native state by separating it from some or all of the naturally occurring components with which it is associated in nature. Such separation or purification can be performed by art-recognized separation techniques such as ion exchange chromatography, affinity chromatography, hydrophobic separation, dialysis, protease treatment, ammonium sulfate precipitation or other protein salt precipitation, centrifugation, size exclusion chromatography, filtration, microfiltration, gel electrophoresis, or gradient separation to remove whole cells, cell debris, impurities, foreign proteins, or enzymes that are not desired in the final composition. Components that provide additional benefits, such as activators, anti-inhibitors, desired ions, compounds to control pH, or other enzymes, or chemicals, can then be further added to the purified or isolated biomolecule composition.
[0221] As used herein, the term "ComK polypeptide" is defined as the product of the comK gene; the gene is a transcription factor that acts as a final autoregulatory control switch before competence develops; involved in activating the expression of late competence genes involved in DNA binding and uptake and recombination (Liu and Zuber, 1998; Hamoen et al., 1998). SEQ ID NO: 43 shows a plasmid (pBL.comK) containing and expressing a comK nucleic acid sequence.
[0222] As used herein, "homologous genes" refer to pairs of genes from different, but usually related species that correspond to each other and are identical or very similar to each other. The term encompasses genes separated by speciation (i.e., the development of new species) (e.g., orthologous genes) and genes separated by genetic duplication (e.g., paralogous genes).
[0223] As used herein, "orthologs" and "orthologous genes" refer to genes in different species that have evolved from a common ancestral gene (i.e., homologous genes) through speciation. Typically, orthologs retain the same function during evolution. The identification of orthologs can be used for reliable prediction of gene function in newly sequenced genomes.
[0224] As used herein, "paralogs" and "paralogous genes" refer to genes associated with repetitions in a genome. Although orthologs maintain the same function during evolution, paralogs develop new functions, even if some functions are usually associated with the original functions. Examples of paralogous genes include, but are not limited to, genes encoding trypsin, chymotrypsin, elastase, and thrombin, all of which are serine proteases and occur together in the same species.
[0225] As used herein, "homology" refers to sequence similarity or identity, with identity being preferred. Such homology is determined using standard techniques known in the art (see, e.g., Smith and Waterman, 1981; Needleman and Wunsch, 1970; Pearson and Lipman, 1988; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, Wisconsin) and Devereux et al., 1984).
[0226] As used herein, a "similar sequence" is a sequence in which the function of the gene is substantially the same as that of a gene derived from a Bacillus cell. In addition, a similar gene comprises at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% sequence identity to the sequence of a Bacillus species cell. Similar sequences are determined by known sequence alignment methods. A commonly used alignment method is BLAST, although there are other methods that can also be used to align sequences.
[0227] As used herein, the term "hybridization" refers to the process of joining a nucleic acid strand to a complementary strand through base pairing, as known in the art. A nucleic acid sequence is considered to "selectively hybridize" to a reference nucleic acid sequence if the two sequences specifically hybridize to each other under medium to high stringency hybridization and wash conditions. Hybridization conditions are based on the melting temperature (T) of the nucleic acid binding complex or probe. m ). For example, “maximum stringency” usually occurs at about T m - 5℃(than the probe's T m Low 5°); "High Strict" occurs below T m About 5°C-10°C; "moderate stringency" occurs when the probe's T m About 10℃-20℃ lower; and "low stringency" occurs below T m About 20°C-25°C. Functionally, maximum stringency conditions can be used to identify sequences that have strict identity or near strict identity with the hybridization probe; while medium or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs. Medium and high stringency hybridization conditions are well known in the art. Examples of high stringency conditions include the following hybridization: at about 42°C in 50% formamide, 5X SSC, 5X Denhardt's solution, 0.5% SDS and 100 pg / ml denatured carrier DNA, followed by washing twice in 2X SSC and 0.5% SDS at room temperature (RT), and washing twice more in 0.1X SSC and 0.5% SDS at 42°C. An example of moderate stringency conditions includes overnight incubation at 37° C. in a solution comprising 20% formamide, 5× SSC (150 mM NaCI, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5× Denhardt's solution, 10% dextran sulfate, and 20 mg / ml denatured sheared salmon sperm DNA, followed by washing the filter in 1× SSC at about 37° C.-50° C. Those skilled in the art will know how to adjust temperature, ionic strength, etc. to accommodate factors such as probe length, if necessary.
[0228] As used herein, "recombinant" includes reference to a cell or vector that has been modified by the introduction of a heterologous nucleic acid sequence, or the cell is derived from a cell that has been so modified. Thus, for example, a recombinant cell expresses genes in the same form not found in the native (non-recombinant) form of the cell or expresses native genes that are otherwise abnormally expressed, underexpressed, or not expressed at all (due to deliberate human intervention). "Recombination" or the production of a "recombined" nucleic acid is typically an assembly of two or more nucleic acid fragments, wherein the assembly produces a chimeric gene.
[0229] As used herein, "flanking sequence" refers to any sequence upstream or downstream of the sequence in question (for example, for gene ABC, gene B is flanked by A and C gene sequences). In certain embodiments, the input sequence has a homology box on each side flank. In another embodiment, the input sequence and the homology box are included in a unit with a stuffing sequence on each side flank. In certain embodiments, the flanking sequence is only present on one side (3' or 5'), but in a preferred embodiment, each side of the sequence has a flanking sequence. The sequence of each homology box is homologous to the sequence in the Bacillus chromosome. These sequences guide the integration position of the new construct in the Bacillus chromosome and which part of the Bacillus chromosome will be replaced by the input sequence. In other embodiments, the 5' and 3' ends of the selective marker are flanked by a polynucleotide sequence comprising the part of the chromosomal segment of inactivation. In certain embodiments, the flanking sequence is only present on one side (3' or 5'), and in other embodiments, it is present on each side of the flanking sequence.
[0230] As used herein, the term "stuffer sequence" refers to any additional DNA that flanks a homology box (usually a vector sequence). However, the term encompasses any non-homologous DNA sequence. Without being limited by any theory, the stuffer sequence provides a non-critical target for cells to initiate DNA uptake.
[0231] II. Ribosomal RNA Promoter Sequences
[0232] As generally described above, certain embodiments of the present disclosure relate to novel promoter (nucleic acid) sequences described herein. In certain embodiments, these novel promoter sequences are operatively linked to a gene or ORF encoding a POI, wherein they are particularly suitable for large-scale production of industrially relevant proteins. In certain embodiments, such novel promoter sequences are synthetic variants of natural Bacillus species ribosomal RNA (rrn) promoter (nucleic acid) sequences.
[0233] For example, as presented in the background technology section above, International PCT Publication No. WO2013 / 086219 generally discloses promoters, expression vectors, microorganisms, and methods for producing polynucleotides encoding target proteins, the polynucleotides comprising ribosomal promoters derived from Bacillus subtilis, wherein the ribosomal promoter sequences described can be used for enhanced protein production in Gram-positive microbial cells. These ribosomal RNA and ribosomal protein promoter sequences include certain Bacillus subtilis ribosomal RNA promoters (abbreviated as "rrn"), such as rrnB, rrnI, and rrnE, and certain Bacillus subtilis ribosomal protein promoters (abbreviated as "rps"), such as rpsD and rpsJ.
[0234] In contrast, as presented and described in the Examples section below, applicants have identified novel mutant / variant promoter sequences derived from such rrn promoter (nucleic acid) sequences. More particularly, during conventional synthesis of DNA for assembly into Bacillus expression constructs, applicants altered the sequence of the rrn promoter to facilitate DNA assembly of the constructs, during these alterations, applicants identified certain Bacillus subtilis rrnIp2 promoter mutants (e.g., variant / mutant rrnIp2 promoter sequences, such as SEQ ID NOs: 40, 58, and 59) that express / produce increased amounts of an operably linked reporter gene compared to the native rrnIp2 promoter sequence.
[0235] For example, as presented and described in Example 1, the applicant constructed an aprE Cas9 targeting vector for introducing an expression cassette into the aprE locus of Bacillus subtilis. Thus, to produce a guide RNA (gRNA) expression cassette, the DNA encoding the gRNA is effectively linked to a promoter sequence and a terminator sequence effective in a Bacillus species cell, such that the promoter is located upstream (5′) of the DNA encoding the gRNA, and the terminator is located downstream (3′) of the DNA encoding the gRNA. In addition, Example 2 of the present disclosure further describes the construction of a Bacillus species (progeny) cell comprising an introduced hydrolase expression cassette. More specifically, such Bacillus sp. cells comprise a hydrolase expression cassette having (1) a DNA sequence homologous to the 5′ flanking region of the yhfN gene (SEQ ID NO:38), the DNA sequence operably linked to (2a) a DNA sequence encoding the native Bacillus subtilis rrnIp2 promoter (SEQ ID NO:39) or (2b) a DNA sequence encoding the novel (synthetic) variant rrnIp2-1 promoter (SEQ ID NO:40), the promoter DNA sequence (3) operably linked to a DNA sequence encoding an exemplary protein of interest (i.e., a hydrolase), the DNA sequence encoding the exemplary protein of interest (4) operably fused to a DNA sequence encoding a Bacillus amyloliquefaciens apr terminator sequence (SEQ ID NO:41), wherein the promoter is located upstream (5′) of the DNA sequence encoding the hydrolase, and the terminator is located downstream (3′) of the DNA encoding the hydrolase. In addition, such expression cassettes are effectively fused to a DNA sequence homologous to the 3′ flanking region of the yhfN gene (SEQ ID NO: 42). For example, a Bacillus sp. (progeny) cell colony containing a hydrolase expression cassette with a native rrnIp2 promoter (SEQ ID NO: 39) was stored and designated as strain "SS066", while a Bacillus sp. (progeny) cell colony containing a hydrolase expression cassette with a modified rrnIp2-1 promoter (SEQ ID NO: 40) was stored and designated as strain "SS065".
[0236] Example 3 of the present disclosure further describes that the production of hydrolases (i.e., proteases) by Bacillus sp. cells (e.g., Bacillus sp. cells SS066) or Bacillus sp. cells (e.g., Bacillus sp. cells SS065) comprising a hydrolase expression cassette with a native rrnIp2 promoter (i.e., Example 3; proteases) was evaluated under small-scale conditions. More specifically, the protease concentration in the whole cell broth was determined using the suc-AAPF-pNA assay after forty (40) hours of growth. For example, Table 5 (Example 3) shows the (normalized) relative protease expression of SS065 cells (i.e., comprising the rrnIp2-1 promoter; SEQ ID NO: 40) relative to SS066 cells (i.e., comprising the native rrnIp2 promoter; SEQ ID NO: 39), which indicates that the protease activity was increased by approximately 2-fold.
[0237] Likewise, Example 4 of the present disclosure presents a Bacillus sp. cell comprising an exemplary hydrolase expression cassette (i.e., Example 4; amylase). More specifically, the amylase expression cassette described in Example 4 is introduced into a Bacillus licheniformis cell comprising (1) an amylase expression cassette under the control of a native rrnIp2 promoter (SEQ ID NO: 39) or (2) an amylase expression cassette under the control of a modified rrnIp2-1 promoter (SEQ ID NO: 40). More specifically, halo positive transformants of the native rrnIp2 amylase cassette and the modified rrnIp2-1 amylase cassette were streak purified on L agar containing 1% (w / v) insoluble starch to purify single colonies, wherein the colony with the sequence-verified cassette of the rrnIp2_amylase cassette was stored and named "BF399", and the colony with the sequence-verified cassette of the rrnIp2-1_amylase cassette was stored and named "BF401".
[0238] Example 5 of the present disclosure further assayed Bacillus sp. cells (i.e., cells BF399 and BF401) comprising the amylase expression cassette constructed in Example 4. For example, as presented in Table 9, the expression / production of amylases comprising an amylase expression cassette of the native rrnIp2 promoter (i.e., cassette SEQ ID NO: 44) and an amylase expression cassette comprising a variant rrnIp2-1 promoter (i.e., cassette SEQ ID NO: 45) were tested to determine the effects of these different promoters on amylase production in Bacillus sp. cells. More specifically, as presented in Table 9, Bacillus sp. cells comprising a variant rrnIp2-1 promoter (SEQ ID NO: 40; i.e., cassette SEQ ID NO: 45) produced an average of 30% more amylase than Bacillus sp. cells comprising a native rrnIp2 promoter (i.e., cassette SEQ ID NO: 44).
[0239] Thus, as generally described herein, certain embodiments of the present disclosure relate to compositions and methods for producing / constructing Bacillus sp. cells (eg, protein-producing host cells, cell factories) having an increased protein production phenotype, etc.
[0240] III. Sequence of the promoter region of Bacillus licheniformis amyL
[0241] As generally set forth above, certain embodiments of the present disclosure relate to novel promoter (nucleic acid) sequences described herein. Thus, in certain embodiments, the novel promoter sequences described herein are operatively linked to a gene or ORF encoding a POI, and the novel promoter sequences are particularly suitable for large-scale production of industrially relevant proteins. For example, certain embodiments relate to novel promoter sequence regions comprising an upstream promoter sequence operatively linked to a downstream 5′-UTR sequence, as generally described herein. In certain embodiments, such novel promoter sequence regions are synthetic (modified) variants of the native Bacillus licheniformis amyL promoter (nucleic acid) sequence.
[0242] For example, as described in Section II above (e.g., see Figure 1 ) Generally stated, when the 3′ adenine (A) at nucleotide positions 89, 90, and 91 of the native rrnIp2 promoter sequence (SEQ ID NO:39) is changed to thymine (T) at nucleotide position 89, guanine (G) at nucleotide position 90, and thymine (T) at nucleotide position 91 of the rrnIp2-1 promoter sequence (SEQ ID NO:40; SEQ ID NO:58), in (T GT) The expression of the target gene under the control of the modified rrnIp2-1 promoter (SEQ ID NO:40; SEQ ID NO:58) is significantly enhanced relative to the expression of the same target gene expressed under the control of the native rrnIp2 promoter (SEQ ID NO:39). Based on these surprising and unexpected observations of the modified rrnIp2 promoter sequence, the applicants envisioned introducing similar 3' nucleotide modifications into the native Bacillus licheniformis amyL promoter region.
[0243] More specifically, as described in Example 6 below, in certain embodiments, Applicants modified a native Bacillus licheniformis amyL promoter region (designated PamyL-1; SEQ ID NO:64), which comprises a native Bacillus licheniformis amyL promoter sequence (SEQ ID NO:82) and a native Bacillus licheniformis amyL 5′-UTR sequence (SEQ ID NO:84), while a modified amyL promoter region (designated PamyL-2; SEQ ID NO:65) comprises a modified (synthetic) amyL promoter sequence (SEQ ID NO:83) operably linked to a native Bacillus licheniformis amyL 5′-UTR sequence (SEQ ID NO:84), e.g., see Figure 3 and Figure 4 In certain other embodiments, Applicants constructed synthetic (hybrid) promoter regions designated PamyL-3 (SEQ ID NO: 66) and PamyL-4 (SEQ ID NO: 67), wherein the hybrid PamyL-3 promoter region (SEQ ID NO: 66) comprises the native Bacillus licheniformis amyL promoter sequence (SEQ ID NO: 82) operably linked to the native Bacillus subtilis aprE 5′-UTR sequence (SEQ ID NO: 85), and the hybrid PamyL-4 promoter region (SEQ ID NO: 67) comprises a modified Bacillus licheniformis amyL promoter sequence (SEQ ID NO: 83) operably linked to the native Bacillus subtilis aprE 5′-UTR sequence (SEQ ID NO: 85). For example, Figure 5 The putative transcription start site (TSS) is indicated by bold nucleotides, followed by the 5′-UTR sequence indicated by italic nucleotides, and the double-underlined “ G ” nucleotides were used to help visualize the TSS of PamyL-3 (relative to PamyL-4).
[0244] Thus, a heterologous (truncated) pullulanase expression cassette was introduced into Bacillus licheniformis cells as generally described in Example 6. More specifically, a (truncated) pullulanase expression cassette was introduced into Bacillus licheniformis cells, wherein the cells comprised (a) an expression cassette under the control of the native Bacillus licheniformis amyL promoter region (i.e., PamyL-1; SEQ ID NO: 64), (b) an expression cassette under the control of a modified promoter region PamyL-2 (SEQ ID NO: 65), (c) an expression cassette under the control of a modified promoter region PamyL-3 (SEQ ID NO: 66), or (d) an expression cassette under the control of a modified promoter region PamyL-4 (SEQ ID NO: 67). For example, as described in Example 6, colonies with a sequence-verified cassette for the PamyL-1 pullulanase cassette (SEQ ID NO:78) were streaked purified, stored and named "PamyL-Pulltr."; colonies with a sequence-verified cassette for the PamyL-2 pullulanase cassette (SEQ ID NO:79) were streaked purified, stored and named "LDN461"; colonies with a sequence-verified cassette for the PamyL-3 pullulanase cassette (SEQ ID NO:80) were streaked purified, stored and named "LDN462"; and colonies with a sequence-verified cassette for the PamyL-4 pullulanase cassette (SEQ ID NO:81) were streaked purified, stored and named "LDN463."
[0245] More specifically, as further described in Example 7, Applicants assayed Bacillus cells (strains) containing introduced (truncated) pullulanase expression cassettes to determine the effects of the different promoter regions on the production of the heterologous pullulanase protein. For example, the data presented in Example 7 show that Bacillus strains containing the PamyL-2 pullulanase cassette (SEQ ID NO: 79; e.g., strain LDN461) produce an average of 78% more pullulanase than Bacillus strains containing the PamyL-1 pullulanase cassette (SEQ ID NO: 78; strain PamyL-Pulltr.). Similarly, the data presented in Example 7 show that Bacillus strains containing the PamyL-4 pullulanase cassette (SEQ ID NO: 81; strain LDN463) produce an average of 16% more pullulanase than Bacillus strains containing the PamyL-3 pullulanase cassette (SEQ ID NO: 80; strain LDN462).
[0246] Thus, as generally described herein, certain embodiments of the present disclosure relate to compositions and methods for producing / constructing Bacillus sp. cells (eg, protein-producing host cells, cell factories) having an increased protein production phenotype, etc.
[0247] IV. Molecular Biology
[0248] As generally set forth above, certain embodiments of the present disclosure relate to modified Bacillus species (progeny) cells derived from parent Bacillus cells. More particularly, certain other embodiments relate to modified Bacillus species (progeny) cells and methods for producing and constructing such modified Bacillus species cells (e.g., protein production host cells, cell factories) having increased protein productivity phenotypes, etc. Therefore, certain other embodiments relate to mutants of parent Bacillus species cells, the mutants comprising one or more genetic modifications (i.e., relative to the parent cell).
[0249] As presented herein, such novel promoter (nucleic acid) sequences are particularly useful for expressing a gene or ORF encoding a target protein in a Bacillus species cell. Other embodiments relate to novel promoter (nucleic acid) sequences, which are included in their novel expression cassettes. Therefore, certain other embodiments relate to modified Bacillus species cells, which cells include one or more heterologous expression constructs introduced therein. Certain other embodiments relate to an isolated target protein (POI) produced by a modified Bacillus species cell of the present disclosure. Therefore, in certain embodiments, one or more promoter sequences are effectively connected to a gene or ORF encoding a POI. In certain other embodiments, one or more promoter sequences also include nucleotides located upstream (5') and effectively connected thereto. In other embodiments, a gene or ORF also includes nucleotides located downstream (3') and effectively connected thereto.
[0250] Therefore, certain embodiments of the present disclosure relate to methods for genetically modifying Bacillus species cells (e.g., via introduction, substitution, and / or removal of one or more nucleotides in a gene, ORF, promoter, terminator, 5′-UTR, 3′-UTR, etc.). Therefore, methods for genetically modifying Bacillus species cells include, but are not limited to: (a) introduction, substitution, and / or removal of one or more nucleotides in a given nucleic acid sequence, (b) gene disruption, (c) gene conversion, (d) gene deletion, (e) gene downregulation, (f) Cas9-mediated editing, (g) site-specific mutagenesis, and / or (h) random mutagenesis. Therefore, in certain embodiments, parental Bacillus species cells are modified using methods well known in the art, such as insertion, disruption, substitution or deletion in a polynucleotide sequence of interest, etc.
[0251] For example, in certain embodiments, a part of the gene to be modified can be a coding region or a regulatory element required for expression of the coding region. In certain embodiments, methods known in the art are used to modify Bacillus species nucleic acid sequences (e.g., genes, ORFs, promoters, 5′-UTR, etc.). In certain embodiments, promoter (nucleic acid) sequences are modified using methods known in the art. In other embodiments, promoters derived from natural Bacillus species are modified using methods known in the art. In certain other embodiments, variant Bacillus species promoters of the present disclosure are synthetic sequences (e.g., rrnIp2-1 promoter; SEQ ID NO:40).
[0252] Therefore, in certain embodiments, modified Bacillus species cells are constructed by gene deletion.Gene deletion technology can partially or completely remove one or more genes, thereby eliminating their expression or expressing non-functional (or activity-reduced) protein products.In such methods, the deletion of one or more genes can be completed by using a plasmid to carry out homologous recombination, and the plasmid has been constructed into 5' and 3' districts containing gene flanks continuously.Continuous 5' and 3' districts can be introduced into Bacillus cells, for example, on a temperature-sensitive plasmid (such as pE194), combined with the second selectable marker at a permissive temperature to allow plasmids to be established in cells.Then the cell is moved to a non-permissive temperature to select cells with a plasmid integrated into the chromosome at one of the homologous flanking regions.The selection of plasmid integration is realized by selecting the second selectable marker.After integration, the recombination event at the second homologous flanking region is stimulated by moving the cell to a permissive temperature for several generations without selecting.Cells are plated to obtain single colonies, and check whether the colonies lose two selectable markers (see, for example, Perego, 1993). Thus, one skilled in the art can readily identify nucleotide regions (suitable for complete or partial deletion) in the coding sequence of a gene and / or in the non-coding sequence of a gene.
[0253] In other embodiments, the modified Bacillus sp. cells of the present disclosure are constructed by introducing, replacing, or removing one or more nucleotides in a gene or a regulatory element required for transcription or translation thereof. For example, as described herein, certain modified promoter (nucleic acid) sequences of the present disclosure comprise nucleotide substitutions (e.g., nucleotide positions 30, 89, 90, and 91). Such modifications can be accomplished by techniques known in the art (e.g., site-directed mutagenesis or PCR-generated mutagenesis) according to methods known in the art (e.g., see Botstein and Shortle, 1985; Lo et al., 1985; Higuchi et al., 1988; Shimada, 1996; Ho et al., 1989; Horton et al., 1989; and Sarkar and Sommer, 1990).
[0254] In another embodiment, the modified Bacillus species cell is constructed by the process of gene conversion (e.g., see Iglesias and Trautner, 1983). For example, in the gene conversion method, the nucleic acid sequence corresponding to one or more genes is induced in vitro to produce a defective nucleic acid sequence, and then the defective nucleic acid sequence is transformed into the parent Bacillus cell to produce the defective gene. Through homologous recombination, the defective nucleic acid sequence replaces the endogenous gene. It may be desirable that the defective gene or gene fragment also encodes a marker that can be used to select a transformant containing the defective gene. For example, the defective gene can be combined with a selectable marker and introduced into a non-replicating or temperature-sensitive plasmid. The selection of plasmid integration is achieved by selecting markers under conditions that do not allow plasmid replication. The selection of the second recombination event that causes gene replacement is achieved by checking the colony loss selectable marker and obtaining mutant genes (Perego, 1993). Alternatively, the defective nucleic acid sequence can contain the insertion, substitution, or deletion of one or more nucleotides of the gene, as described below.
[0255] In other embodiments, modified Bacillus species cells are produced / constructed via CRISPR-Cas9 editing. For example, the Bacillus species promoter sequence of the present disclosure can be edited (or destroyed, deleted, downregulated) by a nucleic acid-guided endonuclease, which finds its target DNA by binding to a guide RNA (e.g., Cas9) and Cpf1 or a guide DNA (e.g., NgAgo), which recruits the endonuclease to the target sequence on the DNA, wherein the endonuclease can produce single-strand or double-strand breaks in the DNA. This targeted DNA break becomes a substrate for DNA repair and can be recombined with a provided editing template to modify the promoter sequence (e.g., see Example 1). Therefore, a gene encoding a nucleic acid-guided endonuclease (for this purpose, Cas9 from Streptococcus pyogenes (S.pyogenes)) or a codon-optimized gene encoding a Cas9 nuclease is effectively connected to a promoter active in a Bacillus species cell and a terminator active in a Bacillus cell, thereby producing a Bacillus Cas9 expression cassette. Similarly, one skilled in the art can easily identify one or more target sites that are specific to the promoter of interest. For example, in order to construct a DNA construct encoding a gRNA (for a target promoter site of interest), a variable targeting (VT) domain will include nucleotides of a target site adjacent to the motif (TGG) 5′ of the (PAM) protospacer sequence, which is fused to a DNA encoding the Cas9 endonuclease recognition domain (CER) of Streptococcus pyogenes Cas9. DNA encoding the VT domain and DNA encoding the CER domain are combined to produce DNA encoding gRNA. Therefore, the Bacillus expression cassette of the gRNA is produced by effectively connecting the DNA encoding the gRNA to a promoter active in a Bacillus cell and a terminator active in a Bacillus cell. In certain embodiments, DNA breaks induced by endonucleases are repaired / replaced with input sequences.
[0256] For example, in order to accurately repair the DNA breakage produced by the above-mentioned Cas9 expression cassette and gRNA expression cassette, a nucleotide editing template is provided so that the DNA repair mechanism of the cell can utilize the editing template. For example, about 500bp upstream (5') of the targeting promoter can be fused with about 500bp downstream (3') of the targeting promoter to produce an editing template, which is used by the mechanism of the bacillus host to repair the DNA breakage produced by RGEN. Many different methods (for example, protoplast fusion, electroporation, natural competence, or induction competence) can be used to deliver Cas9 expression cassette, gRNA expression cassette and editing template to cells together. By amplifying the locus with forward and reverse primers, the transformed cells are screened by amplifying the target locus by PCR. These primers can amplify the wild-type locus or the modified locus edited by RGEN. These fragments are then sequenced using sequencing primers to identify the edited colonies.
[0257] In yet other embodiments, modified Bacillus sp. cells are constructed by random or specific mutagenesis using methods well known in the art, including, but not limited to, chemical mutagenesis (see, e.g., Hopwood, 1970) and transposition (see, e.g., Youngman et al., 1983). Modification of genes or promoters can be performed by mutagenizing parental cells and screening for mutant cells in which gene expression has been altered. Mutagenesis can be specific or random and can be performed, for example, by using a suitable physical or chemical mutagen, by using a suitable oligonucleotide, or by performing PCR-generated mutagenesis on a DNA sequence. In addition, mutagenesis can be performed by using any combination of these mutagenesis methods.
[0258] Examples of physical or chemical mutagens suitable for the purposes of the present invention include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl-N'-nitrosoguanidine (NTG), o-methylhydroxylamine, nitrous acid, ethyl methanesulfonic acid (EMS), sodium bisulfite, formic acid, and nucleotide analogs. When these agents are used, mutagenesis is generally performed by incubating the parental cells to be mutagenized under appropriate conditions in the presence of the selected mutagen, and selecting cells that exhibit mutations that reduce or eliminate gene expression.
[0259] International PCT Publication No. WO 2003 / 083125 (incorporated herein by reference in its entirety) discloses methods for modifying Bacillus cells, such as using PCR fusion to generate Bacillus deletion strains and DNA constructs to bypass E. coli. International PCT Publication No. WO 2002 / 14490 (incorporated herein by reference in its entirety) discloses methods for modifying Bacillus cells, the methods comprising: (1) construction and transformation of an integrating plasmid (pComK), (2) random mutagenesis of coding sequences, signal sequences, and propeptide sequences, (3) homologous recombination, (4) increasing transformation efficiency by adding non-homologous flanks to transforming DNA, (5) optimizing double cross-over integration, (6) site-directed mutagenesis, and (7) marker-less deletion.
[0260] Those skilled in the art are well aware of suitable methods for introducing polynucleotide sequences into bacterial cells (e.g., E. coli and Bacillus species) (see, e.g., Ferrari et al., 1989; Saunders et al., 1984; Hoch et al., 1967; Mann et al., 1986; Holubova, 1985; Chang et al., 1979; Vorobjeva et al., 1980; Smith et al., 1986; Fisher et al., 1981; and McDonald, 1984). Indeed, transformation methods including protoplast transformation and mid-plate collection, transduction, and protoplast fusion are known and suitable for use in the present disclosure. Transformation methods are particularly preferred for introducing the DNA constructs of the present disclosure into host cells.
[0261] In addition to common methods, in some embodiments, host cells are directly transformed (i.e., before being introduced into host cells, intermediate cells are not used to amplify DNA constructs or otherwise process DNA constructs). Introducing DNA constructs into host cells includes those physical and chemical methods known in the art for introducing DNA into host cells without inserting into plasmids or vectors. Such methods include but are not limited to calcium chloride precipitation, electroporation, naked DNA, liposomes, etc. In additional embodiments, DNA constructs are co-transformed with plasmids without inserting the plasmids. In other embodiments, by methods known in the art, selective markers are deleted or substantially excised from modified Bacillus strains (e.g., Stahl et al., 1984 and Palmeros et al., 2000). In some embodiments, the vector is decomposed from the host chromosome, the flanking regions are left on the chromosome, and the inherent chromosomal regions are removed.
[0262] Methods for screening and generating promoter libraries with a range of activities (promoter strengths) in Bacillus cells are described in International PCT Publication No. WO 2003 / 089604.
[0263] V. Cultivation of Bacillus cells for production of target protein
[0264] In other embodiments of the present disclosure, the Bacillus species cells constructed and described herein comprise an enhanced protein productivity phenotype. More specifically, the modified Bacillus species (progeny) cells of the present disclosure comprise an enhanced protein productivity phenotype relative to the parent Bacillus species cells from which they are derived (when the parent cell and the progeny cell are cultured under the same conditions). Therefore, certain embodiments of the present disclosure relate to methods of expressing / producing a protein of interest (POI), which methods generally include fermenting / culturing such cells.
[0265] Fermentation methods well known in the art can be used to ferment modified and unmodified Bacillus species cells of the present disclosure. In certain embodiments, cells are cultured under batch or continuous fermentation conditions. Classical batch fermentation is a closed system in which the composition of the culture medium is set at the beginning of the fermentation, and the composition does not change during the fermentation. At the beginning of the fermentation, the culture medium is inoculated with one or more desired organisms. In this method, fermentation is allowed to occur without adding any components to the system. Typically, batch fermentation meets the qualification of "batch" with respect to adding a carbon source, and control factors (such as pH and oxygen concentration) are often attempted. The metabolites and biomass composition of the batch system are constantly changing until the fermentation stops. In a typical batch culture, cells can progress to a high growth logarithmic phase through a static lag phase, and finally enter a stable phase in which the growth rate decreases or stops. If not treated, cells in the stable phase eventually die. Typically, cells in the logarithmic phase are responsible for the mass production of products.
[0266] A suitable variant of a standard batch system is a "fed-batch fermentation" system. In this variant of a typical batch system, substrate is added in increments as the fermentation progresses. Fed-batch systems are useful when catabolite repression may inhibit the metabolism of the cell and when it is desirable to have a limited amount of substrate in the culture medium. The measurement of actual substrate concentration in a fed-batch system is difficult, and is therefore estimated based on the variation of measurable factors such as pH, dissolved oxygen, and the partial pressure of waste gases (e.g., CO ). Batch and fed-batch fermentation are commonly used and are known in the art.
[0267] Continuous fermentation is an open system, in which the defined fermentation medium is continuously added to the bioreactor, while removing an equal amount of conditioned medium for processing. Continuous fermentation usually maintains the culture at a constant high density, wherein the cell is mainly in logarithmic phase growth. Continuous fermentation allows one or more factors affecting cell growth and / or product concentration to be regulated. For example, in one embodiment, limiting nutrients (such as carbon source or nitrogen source) are maintained at a fixed rate, and all other parameters are allowed to be regulated. In other systems, many factors affecting growth can be constantly changed, while the cell concentration measured by the turbidity of the culture medium remains unchanged. Continuous systems strive to maintain the growth conditions of a stable state. Therefore, the cell loss caused by the transfer culture medium should be balanced with the cell growth rate in the fermentation. The method for adjusting the nutrients and growth factors used for the continuous fermentation process and the technology of maximizing the product formation rate are well known in the field of industrial microbiology.
[0268] Thus, in certain embodiments, the POI produced by the transformed (modified) host cells can be recovered from the culture medium by conventional procedures, including separation of the host cells from the culture medium by centrifugation or filtration, or, if desired, disruption of the cells and removal of the supernatant from the cell parts and debris. Typically after clarification, the proteinaceous components of the supernatant or filtrate are precipitated by salt (e.g., ammonium sulfate). The precipitated protein is then dissolved and can be purified by various chromatographic procedures, such as ion exchange chromatography, gel filtration.
[0269] VI. Protein of interest produced by modified cells
[0270] As briefly stated in the preceding section, the cells, strains, polynucleotides, promoters, expression constructs and methods thereof disclosed herein can be used to produce commercially important proteins. The protein of interest (POI) disclosed herein can be any endogenous or heterologous protein, and it can be a variant of such a POI. The protein can contain one or more disulfide bridges, or be a protein whose functional form is a monomer or a polymer, i.e., the protein has a quaternary structure and is composed of multiple identical (homologous) or non-identical (heterologous) subunits, wherein the POI or its variant POI is preferably a POI having a desired property.
[0271] For example, in certain embodiments, the modified Bacillus species (progeny) cell comprises an increased protein titer relative to the parent Bacillus species cell from which it is derived, wherein the protein titer is defined as the amount of protein / volume (g / L). For example, titer can be measured by methods known in the art (e.g., ELISA, HPLC, Bradford assay, LC / MS, etc.). Thus, in certain embodiments, the modified Bacillus species (progeny) cell comprises at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more protein titer increase relative to the parent Bacillus species cell from which it is derived.
[0272] In certain embodiments, the modified Bacillus sp. (progeny) cell exhibits increased volumetric productivity relative to the parent Bacillus sp. cell from which it is derived, wherein volumetric productivity is defined as the amount (g) of protein produced during fermentation / bioreactor nominal volume (L) / total fermentation time (h). For example, volumetric productivity can be measured by methods known in the art (e.g., ELISA, HPLC, Bradford assay, LC / MS, etc.). Thus, in certain embodiments, the modified Bacillus sp. (progeny) cell comprises at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more volumetric productivity increase relative to the parent Bacillus sp. cell from which it is derived.
[0273] In certain other embodiments, the modified Bacillus sp. (progeny) cell exhibits an increased total protein yield relative to the parent Bacillus sp. cell from which it is derived, wherein the total protein yield is defined as the amount of protein produced per gram of carbohydrate supplied (g). Thus, as used herein, the total protein yield (g / g) can be calculated using the following equation:
[0274] Y f =T p / T c
[0275] Among them, "Y f ” is the total protein yield (g / g), “T p ” is the total protein produced during fermentation (g), and “T c” is the total carbohydrate (g) fed during the fermentation (bioreactor) operation. In certain embodiments, the total protein yield of the modified Bacillus sp. (progeny) cell is increased by at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more relative to the parental Bacillus sp. cell from which it is derived.
[0276] Total protein yield can also be described as carbon conversion efficiency / carbon yield, for example, as a percentage (%) of the supplied carbon incorporated into the total protein. Thus, in certain embodiments, the modified Bacillus species (daughter) cell comprises an increased carbon conversion efficiency (e.g., an increase in the percentage (%) of the supplied carbon incorporated into the total protein) relative to the parent Bacillus species cell from which it is derived. In certain embodiments, the increase in the carbon conversion efficiency of the modified cell (i.e., relative to the parent cell) is an increase of at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more.
[0277] In certain embodiments, the modified Bacillus sp. (progeny) cell exhibits an increased POI specific productivity (Qp) relative to the parent Bacillus sp. cell from which it is derived. For example, detection of specific productivity (Qp) is a suitable method for evaluating protein production rate. Specific productivity (Qp) can be determined using the following equation:
[0278] “Qp=gP / gDCW·hr”
[0279] Wherein "gP" is the grams of protein produced in the tank; "gDCW" is the grams of dry cell weight (DCW) in the tank, and "hr" is the fermentation time in hours starting from the inoculation time, including production time as well as growth time. Thus, in certain embodiments, the modified Bacillus sp. (progeny) cell comprises an increase in specific productivity (Qp) of at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more relative to the parental Bacillus sp. cell from which it is derived.
[0280] In certain embodiments, the POI or its variant POI is selected from the group consisting of: acetylesterase, aminopeptidase, amylase, arabinase, arabinofuranosidase, carbonic anhydrase, carboxypeptidase, catalase, cellulase, chitinase, rennetinase, cutinase, deoxyribonuclease, epimerase, esterase, α-galactosidase, β-galactosidase, α-glucanase, glucan lyase, endo-β-glucanase, glucoamylase, glucose oxidase, α-glucosidase, β-glucosidase, glucuronidase, glycosyl hydrolyzing enzyme. Enzymes, hemicellulases, hexose oxidases, hydrolases, invertases, isomerases, laccases, ligases, lipases, lyases, mannanases, mannosidases, oxidases, oxidases, oxidoreductases, pectin lyases, pectin acetylesterases, pectin depolymerases, pectin methylesterases, pectinolytic enzymes, perhydrolases, polyol oxidases, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, peptidases, rhamnogalacturonases, ribonucleases, transferases, transporters, transglutaminases, xylanases, hexose oxidases, and combinations thereof.
[0281] In certain embodiments, the POI or variant POI thereof is selected from an Enzyme Commission (EC) number selected from the group consisting of EC 1, EC 2, EC 3, EC 4, EC 5, or EC 6.
[0282] For example, in certain embodiments, the POI is an oxidoreductase, including but not limited to an EC1 (oxidoreductase) enzyme selected from the group consisting of EC 1.10.3.2 (e.g., laccase), EC 1.10.3.3 (e.g., L-ascorbate oxidase), EC 1.1.1.1 (e.g., alcohol dehydrogenase), EC 1.11.1.10 (e.g., chloride peroxidase), EC 1.11.1.17 (e.g., peroxidase), EC 1.1.1.27 (e.g., L-lactate dehydrogenase), EC 1.1.1.47 (e.g., glucose 1-dehydrogenase), EC 1.1.3.X (e.g., glucose oxidase), EC 1.1.3.10 (e.g., pyranose oxidase), EC 1.13.11.X (e.g., dioxygenase), EC 1.13.11.12 (e.g., linoleate 13S-lipoxygenase), EC EC 1.1.3.13 (e.g., alcohol oxidases), EC 1.14.14.1 (e.g., monooxygenases), EC 1.14.18.1 (e.g., monophenolmonooxigenases), EC 1.15.1.1 (e.g., superoxide dismutases), EC 1.1.5.9 (formerly EC 1.1.99.10, e.g., glucose dehydrogenases), EC 1.1.99.18 (e.g., cellobiose dehydrogenases), EC 1.1.99.29 (e.g., pyranose dehydrogenases), EC 1.2.1.X (e.g., fatty acid reductases), EC 1.2.1.10 (e.g., acetaldehyde dehydrogenases), EC 1.5.3.X (e.g., fructosylamine reductases), EC 1.8.1.X (e.g., disulfide reductases), and EC 1.8.3.2 (e.g., thiol oxidases).
[0283] In certain embodiments, the POI is a transferase, including but not limited to an EC 2 (transferase) enzyme selected from the group consisting of EC 2.3.2.13 (e.g., transglutaminase), EC 2.4.1.X (e.g., hexosyltransferase), EC 2.4.1.40 (e.g., alternasucrase), EC 2.4.1.18 (e.g., 1,4 α-glucan branching enzyme), EC 2.4.1.19 (e.g., cyclomaltodextrin glucanotransferase), EC 2.4.1.2 (e.g., dextrin glucanase), EC 2.4.1.20 (e.g., cellobiose phosphorylase), EC 2.4.1.25 (e.g., 4-α-glucanotransferase), EC 2.4.1.333 (e.g., 1,2-β-oligoglucan phosphotransferase), EC 2.4.1.4 (e.g., amylosucrase), EC EC 2.4.1.5 (e.g., glucansucrase), EC 2.4.1.69 (e.g., galactoside 2-α-L-fucosyltransferase), EC 2.4.1.9 (e.g., inulinsucrase), EC 2.7.1.17 (e.g., xylulokinase), EC 2.7.7.89 (formerly EC 3.1.4.15, e.g., [glutamine synthetase]-adenosine-L-tyrosine phosphorylase), EC 2.7.9.4 (e.g., α-glucan kinase), and EC 2.7.9.5 (e.g., phosphoglucan kinase).
[0284] In other embodiments, the POI is a hydrolase, including but not limited to an EC 3 (hydrolase) enzyme selected from the group consisting of EC 3.1.XX (e.g., esterase), EC 3.1.1.1 (e.g., pectinase), EC 3.1.1.14 (e.g., chlorophyllase), EC 3.1.1.20 (e.g., tannase), EC 3.1.1.23 (e.g., glyceride acyl hydrolase), EC 3.1.1.26 (e.g., galactolipase), EC 3.1.1.32 (e.g., phospholipase A1), EC 3.1.1.4 (e.g., phospholipase A2), EC 3.1.1.6 (e.g., acetyl esterase), EC 3.1.1.72 (e.g., acetyl xylan esterase), EC 3.1.1.73 (e.g., ferulic acid esterase), EC 3.1.1.74 (e.g., cutinase), EC EC 3.1.1.86 (e.g., rhamnogalacturonate acetylesterase), EC 3.1.1.87 (e.g., fumonisin B1 esterase), EC 3.1.26.5 (e.g., ribonuclease P), EC 3.1.3.X (e.g., phosphomonoester hydrolase), EC 3.1.30.1 (e.g., Aspergillus nuclease S1), EC 3.1.30.2 (e.g., Serratia marcescens nuclease), EC 3.1.3.1 (e.g., alkaline phosphatase), EC 3.1.3.2 (e.g., acid phosphatase), EC 3.1.3.8 (e.g., 3-phytase), EC 3.1.4.1 (e.g., phosphodiesterase I), EC 3.1.4.11 (e.g., phosphoinositide phospholipase C), EC 3.1.4.3 (e.g., phospholipase C), EC EC 3.1.4.4 (e.g., phospholipase D), EC 3.1.6.1 (e.g., arylsulfatase), EC 3.1.8.2 (e.g., diisopropyl-fluorophosphatase), EC 3.2.1.10 (e.g., oligo-1,6-glucosidase), EC 3.2.1.101 (e.g., mannan endo-1,6-α-mannosidase), EC 3.2.1.11 (e.g., α-1,6-glucan-6-glucanohydrolase), EC 3.2.1.131 (e.g., xylan α-1,2-glucuronidase), EC 3.2.1.132 (e.g., chitosan N-acetylglucosaminylhydrolase), EC 3.2.1.139 (e.g., α-glucuronidase), EC 3.2.1.14 (e.g., chitinase), EC EC 3.2.1.151 (e.g., xyloglucan-specific endo-β-1,4-glucanase), EC 3.2.1.155 (e.g., xyloglucan-specific exo-β-1,4-glucanase), EC 3.2.1.164 (e.g., galactan endo-1,6-β-galactosidase), EC 3.2.1.166 (e.g., galactan endo-1,6-β-galactosidase), EC 3.2.1.170 (e.g., galactan endo-1,6-β-galactosidase), EC 3.2.1.171 (e.g., galactan endo-1,6-β-galactosidase), EC 3.2.1.172 (e.g., galactan endo-1,6-β-galactosidaseEC 3.2.1.17 (e.g., lysozyme), EC 3.2.1.171 (e.g., rhamnogalacturonan hydrolase), EC 3.2.1.174 (e.g., rhamnogalacturonan rhamnohydrolase), EC 3.2.1.2 (e.g., β-amylase), EC 3.2.1.20 (e.g., α-glucosidase), EC 3.2.1.22 (e.g., α-galactosidase), EC 3.2.1.25 (e.g., β-mannosidase), EC 3.2.1.26 (e.g., β-fructofuranosidase), EC 3.2.1.37 (e.g., xylan 1,4-β-xylosidase), EC 3.2.1.39 (e.g., endo-1,3-β-D-glucosidase), EC EC 3.2.1.40 (e.g., α-L-rhamnosidase), EC 3.2.1.51 (e.g., α-L-fucosidase), EC 3.2.1.52 (e.g., β-N-acetylglucosaminidase), EC 3.2.1.55 (e.g., α-N-arabinofuranosidase), EC 3.2.1.58 (e.g., glucan 1,3-β-glucosidase), EC 3.2.1.59 (e.g., glucan endo-1,3-α-glucosidase), EC 3.2.1.67 (e.g., galacturonidase 1,4-α-galacturonidase), EC 3.2.1.68 (e.g., isoamylase), EC 3.2.1.7 (e.g., 1-β-D-fructan fructohydrolase), EC EC 3.2.1.74 (e.g., glucan 1,4-β-glucosidase), EC 3.2.1.75 (e.g., glucan endo-1,6-β-glucosidase), EC 3.2.1.77 (e.g., mannan 1,2-(1,3)-α-mannosidase), EC 3.2.1.80 (e.g., fructan β-fructosidase), EC 3.2.1.82 (e.g., exo-poly-α-galacturonidase), EC 3.2.1.83 (e.g., κ-carrageenanase), EC EC 3.2.1.89 (e.g., arabinogalactan endo-1,4-β-galactosidase), EC 3.2.1.91 (e.g., cellulose 1,4-β-cellobiosidase), EC 3.2.1.96 (e.g., mannosyl-glycoprotein endo-β-N-acetylglucosaminidase), EC 3.2.1.99 (e.g., arabinogalactan endo-1,5-α-L-arabinosidase), EC 3.4.XX (e.g., peptidase), EC 3.4.11.X (e.g., aminopeptidase), EC 3.4.11.1 (e.g., leucyl aminopeptidase), EC 3.4.11.18 (e.g., methionyl aminopeptidase), EC 3.4.13.9 (e.g., Xaa-Pro dipeptidase), EC 3.4.14.5 (e.g., dipeptidyl-peptidase IV), EC 3.4.16.X (e.g., serine carboxypeptidase), EC 3.4.16.5 (e.g., carboxypeptidase C), EC 3.4.19.3 (e.g., pyroglutamyl peptidase I), EC 3.4.21.X (e.g., serine endopeptidase), EC 3.4.21.1 (e.g., chymotrypsin), EC 3.4.21.19 (e.g., glutamyl endopeptidase), EC 3.4.21.26 (e.g., prolyl oligopeptidase), EC 3.4.21.4 (e.g., trypsin), EC 3.4.21.5 (e.g., thrombin), EC 3.4.21.63 (e.g., Aspergillus melleus protease), EC 3.4.21.65 (e.g., thermomycin), EC 3.4.21.80 (e.g., streptomycin A), EC 3.4.22.X (e.g., cysteine endopeptidase), EC 3.4.22.1 (e.g., chymotrypsin), EC 3.4.22.2 (e.g., glutamyl endopeptidase), EC 3.4.22.3 (e.g., prolyl oligopeptidase), EC 3.4.22.4 (e.g., trypsin), EC 3.4.22.5 (e.g., thrombin), EC 3.4.22.6 (e.g., protease), EC EC 3.4.22.14 (e.g., actinidain), EC 3.4.22.2 (e.g., papain), EC 3.4.22.3 (e.g., ficin), EC 3.4.22.32 (e.g., stem bromelain), EC 3.4.22.33 (e.g., fruit bromelain), EC 3.4.22.6 (e.g., chymopapain), EC 3.4.23.1 (e.g., pepsin A), EC 3.4.23.2 (e.g., pepsin B), EC 3.4.23.22 (e.g., Cryptidylcholine pepsin), EC 3.4.23.23 (e.g., Mucor pepsin), EC 3.4.23.3 (e.g., gastric pepsin), EC 3.4.24.X (e.g., metalloendopeptidases), EC EC 3.5.1.2 (e.g., L-glutamine amidohydrolase), EC 3.5.1.3 (e.g., N-acetyl-L-alanine amidohydrolase), EC 3.5.1.4 (e.g., amidase), EC 3.5.1.44 (e.g., protein-L-glutamine amidohydrolase), EC 3.5.1.5 (e.g., urease), EC 3.5.1.6 (e.g., urease), EC 3.5.1.7 (e.g., urease), EC 3.5.1.8 (e.g., N-acyl-aliphatic-L-amino acid amidohydrolase), EC 3.5.1.9 (e.g., N-acetyl-L-alanine amidohydrolase), EC 3.5.1.10 (e.g., N-acyl-aliphatic-L-amino acid amidohydrolase), EC 3.5.1.11 (e.g., penicillin amidase), EC 3.5.1.14 (e.g., N-acyl-aliphatic-L-amino acid amidohydrolase), EC 3.5.1.2 EC 3.5.1.52 (e.g., peptide-N(4)-(N-acetyl-β-glucosaminyl)asparagine amidase), EC 3.5.1.81 (e.g., N-acyl-D-amino acid deacylase), EC 3.5.4.6 (e.g., AMP deaminase), and EC 3.5.5.1 (e.g., nitrilase).
[0285] In other embodiments, the POI is a lyase, including but not limited to an EC 4 (lyase) enzyme selected from the group consisting of EC 4.1.2.10 (e.g., mandelonitrile lyase), EC 4.1.3.3 (e.g., N-acetylneuraminic acid lyase), EC 4.2.1.1 (e.g., carbonic anhydrase), EC 4.2.2.- (e.g., rhamnogalacturonan lyase), EC 4.2.2.10 (e.g., pectin lyase), EC 4.2.2.22 (e.g., pectin trisaccharide-lyase), EC 4.2.2.23 (e.g., rhamnogalacturonan endolyase), and EC 4.2.2.3 (e.g., mannose aldehyde-specific alginate lyase).
[0286] In certain other embodiments, the POI is an isomerase, including but not limited to an EC5 (isomerase) enzyme selected from the group consisting of EC 5.1.3.3 (e.g., aldose 1-epimerase), EC 5.1.3.30 (e.g., D-psicose 3-epimerase), EC 5.4.99.11 (e.g., isomaltulose synthase), and EC 5.4.99.15 (e.g., (1→4)-α-D-glucan 1-α-D-glucosylmutase).
[0287] In yet other embodiments, the POI is a ligase, including but not limited to an EC 6 (ligase) enzyme selected from EC 6.2.1.12 (eg, 4-coumarate:CoA ligase) and EC 6.3.2.28 (eg, L-amino acid α-ligase).
[0288] These and other aspects and embodiments of the strains and methods of the invention will be apparent to the skilled artisan in view of the present description and the following examples.
[0289] Examples
[0290] Certain aspects of the invention may be further understood from the following examples, which should not be construed as limiting. Modifications of materials and methods will be apparent to those skilled in the art.
[0291] Example 1
[0292] Construction of aprE Cas9 targeting vector
[0293] A synthetic polynucleotide encoding the Cas9 protein from Streptococcus pyogenes (SEQ ID NO: 1), comprising an N-terminal nuclear localization sequence (NLS; "APKKKRKV"; SEQ ID NO: 2), a C-terminal NLS ("KKKKLK"; SEQ ID NO: 3), and a deca-histidine tag ("HHHHHHHHHH"; SEQ ID NO: 4) was operably linked to the aprE promoter from Bacillus subtilis (P-aprE) (SEQ ID NO: 5) and amplified using Q5 DNA polymerase (NEB) according to the manufacturer's instructions with the forward (SEQ ID NO: 6) and reverse (SEQ ID NO: 7) primer pairs listed in Table 1 below.
[0294] Table 1
[0295] Forward and reverse primer pairs
[0296] Positive ATATATGAGTAAACTTGGTCTGACAGAATTCCTCCATTTTCTTTCTGCTAT SEQ ID NO:6 Reverse TGCGGCCGCGAATTCGATTACGAATGCCGTCTCCC SEQ ID NO:7
[0297] The backbone (SEQ ID NO: 8) of plasmid pKB320 (SEQ ID NO: 9) was amplified using Q5 DNA polymerase (NEB) (according to the manufacturer's instructions) with the forward (SEQ ID NO: 10) and reverse (SEQ ID NO: 11) primer pairs listed in Table 2 below.
[0298] Table 2
[0299] Forward and reverse primer pairs
[0300] Positive GGGAGACGGCATTCGTAATCGAATTCGCGGCCGCA SEQ ID NO:10 Reverse ATAGCAGAAGAAAATGGAGGAATTCTGTCAGACCAAGTTTACTCATATAT SEQ ID NO:11
[0301] The PCR product was purified using a Zymo clean and concentrate 5 column according to the manufacturer's instructions. Subsequently, the PCR product was assembled using extended overlap extension PCR (POE-PCR) using Q5 polymerase (NEB) mixed with the two fragments in equimolar ratio. The POE-PCR reaction cycle was performed: 98°C for five (5) seconds, 64°C for ten (10) seconds, and 72°C for four (4) minutes and fifteen (15) seconds for 30 cycles. Five (5) μl of POE-PCR (DNA) was transformed into Top10 Escherichia coli (Invitrogen) according to the manufacturer's instructions and selected in lysogenic (L) broth (Miller formula; 1% (w / v) tryptone, 0.5% yeast extract (w / v), 1% NaCl (w / v)) containing fifty (50) μg / ml kanamycin sulfate and solidified with 1.5% agar. The colonies were allowed to grow at 37°C for eighteen (18) hours. Colonies were picked and plasmid DNA was prepared using the Qiaprep DNA mini prep kit (following the manufacturer's instructions) and eluted with fifty-five (55) μl ddH 2 O. Plasmid DNA was Sanger sequenced using the sequencing primers listed in Table 3 below (SEQ ID NOs: 12-20) to verify correct assembly.
[0302] Table 3
[0303] Sequencing primers
[0304] Reverse CCGACTGGAGCTCCTATATTACC SEQ ID NO:12 Reverse GCTGTGGCGATCTGTATTCC SEQ ID NO:13 Positive GTCTTTTAAGTAAGTCTACTCT SEQ ID NO:14 Positive CCAAAGCGATTTTAAGCGCG SEQ ID NO:15 Positive CCTGGCACGTGGTAATTCTC SEQ ID NO:16 Positive GGATTTCCTCAAATCTGACG SEQ ID NO:17 Positive GTAGAAACGCGCCAAATTACG SEQ ID NO:18 Positive GCTGGTGGTTGCTAAAGTCG SEQ ID NO:19 Positive GGACGCAACCCTCATTCATC SEQ ID NO:20
[0305] The correctly assembled plasmid pRF694 (SEQ ID NO: 21) was used to assemble the intermediate plasmid pRF748 (SEQ ID NO: 22). The construction of plasmid pRF748 was performed by cloning the interrupted synthetic gRNA cassette into the NcoI / SalI sites of plasmid pRF694. This cassette was synthetically produced by IDT and contained the Bacillus subtilis rrnIp2 promoter (SEQ ID NO: 39), a synthetic double terminator (SEQ ID NO: 24), the Escherichia coli rpsL gene (SEQ ID NO: 25), DNA encoding the Cas9 endonuclease recognition domain (SEQ ID NO: 26), and the lambda phage T0 terminator (SEQ ID NO: 27).
[0306] The DNA fragment containing the gRNA expression cassette can be assembled into pRF694 using standard molecular biology techniques to generate plasmid pRF748, thereby generating an E. coli-B. subtilis shuttle plasmid containing the Cas9 expression cassette and the gRNA expression cassette.
[0307] The plasmid for introducing the expression cassette into the aprE locus of Bacillus subtilis was assembled using the intermediate plasmid pRF748. More particularly, the yhfN gene (SEQ ID NO:28) in the aprE locus of Bacillus subtilis contains a Cas9 target site (SEQ ID NO:29). The target site can be converted into a DNA sequence (SEQ ID NO:30) encoding a variable targeting (VT) domain by removing the PAM sequence (SEQ ID NO:31). The DNA sequence (SEQ ID NO:30) encoding the VT domain can be effectively fused to the DNA sequence encoding the Cas9 endonuclease recognition domain (CER; SEQ ID NO:26) so that when transcribed by RNA polymerase in the cell, it produces a functional gRNA (SEQ ID NO:32). The DNA encoding the gRNA (SEQ ID NO: 33) can be operably linked to a promoter effective in a Bacillus sp. cell (e.g., Bacillus subtilis rrnIp2 promoter; SEQ ID NO: 39) and a terminator effective in a Bacillus sp. cell (e.g., lambda phage t0 terminator; SEQ ID NO: 26) such that the promoter is located 5′ of the DNA encoding the gRNA and the terminator is located 3′ of the DNA encoding the gRNA, thereby generating a gRNA expression cassette (SEQ ID NO: 34).
[0308] Plasmid pRF793 (SEQ ID NO: 35) targeting the Bacillus subtilis yhfN gene (SEQ ID NO: 36) was generated by amplifying plasmid pRF748 (SEQ ID NO: 22) using Q5 (according to the manufacturer's instructions) and the forward (SEQ ID NO: 37) and reverse (SEQ ID NO: 37) primer pairs listed in Table 4.
[0309] Table 4
[0310] Forward and reverse primer pairs
[0311] Positive TTCAGGATTTGGCCGTGACGGTTTTAGAGCTAGAAATAGCAAGTT SEQ ID NO:37 Reverse CGTCACGGCCAAATCCTGAATTTATTACTATAACATTTAGCTTCTTTTAA SEQ ID NO:38
[0312] These primers amplify the entire plasmid (pRF748), except for the variable targeting region of the gRNA, which produces a fragment in which the 5' and 3' ends overlap and contains the yhfN variable targeting domain. This PCR product was used for an intramolecular assembly reaction using NEBuilder (New England Biolabs) (according to the manufacturer's instructions) to generate plasmid pRF793 (SEQ ID NO: 35), thereby generating an E. coli-Bacillus subtilis shuttle plasmid containing a Cas9 expression cassette and a gRNA expression cassette (which encodes a gRNA targeting yhfN).
[0313] Example 2
[0314] Generation of Bacillus cells containing exemplary expression cassettes
[0315] In this example, applicants introduced a protease expression cassette (e.g., an exemplary POI) into a Bacillus subtilis cell. More specifically, the expression cassette comprises: (1) a DNA sequence homologous to the upstream (5′) flanking region of the yhfN gene (SEQ ID NO: 39), operably fused to (2a) a DNA sequence encoding the native Bacillus subtilis rrnIp2 promoter (SEQ ID NO: 39) or (2b) a genetically modified rrnIp2 sequence thereof, designated herein as the "rrnIp2-1" promoter (SEQ ID NO: 40), the native and modified promoter DNA sequences (3) operably fused to a DNA sequence encoding a mature (subtilisin) protease, the DNA sequence encoding a mature (subtilisin) protease (4) operably fused to a DNA sequence encoding a Bacillus amyloliquefaciens apr terminator sequence (SEQ ID NO: 41), wherein the promoter is located 5′ to the DNA sequence encoding the protease, and the terminator is located 3′ to the DNA sequence encoding the protease. Finally, the expression cassette described above was operatively fused to a DNA sequence homologous to the downstream (3') flanking region of the yhfN gene (SEQ ID NO: 42).
[0316] Thus, in this example, parental Bacillus subtilis cells containing the Bacillus subtilis comK gene (SEQ ID NO:44; introduced at the amyE locus using the PxylA inducible promoter) were grown in fifteen (15) ml of L broth (1% w / v) in one hundred twenty five (125) ml baffled flasks. -1 Tryptone, 0.5% yeast extract w·v -1 、1%NaCl w·v -1) at 37°C and 250 RPM overnight. The overnight culture was diluted to 0.2 (OD) in ten (10) ml of fresh L broth in a one hundred twenty five (125) ml baffled flask. 600 unit).
[0317] The cells were grown at 37°C (250 RPM) until the culture reached 0.9 (OD 600 Units). D-xylose was added to 0.3% (w / v) from a 30% (w / v) stock solution. The cells were grown for an additional two and a half (2.5) hours at 37°C (250RPM) and pelleted at 1700 x g for seven (7) minutes. The cells were resuspended in one quarter (1 / 4) volume of the original culture using the spent culture medium. One hundred (100) μl of the concentrated cells were mixed with approximately one (1) μg of (a) a protease expression cassette comprising the native rrnIp2 promoter (SEQ ID NO:39) or (b) a protease expression cassette comprising the modified rrnIp2-1 promoter (SEQ ID NO:40), and the pRF793 plasmid (SEQ ID NO:34) described in Example 1 was amplified for eighteen (18) hours using rolling circle amplification (Syngis) (according to the manufacturer's instructions). The cell / DNA transformation mixture was plated onto L broth (Miller) containing ten (10) μg / mL kanamycin, 1.6% (w / v) skim milk and solidified with 1.5% (w / v) agar. Colonies were allowed to form at 37°C.
[0318] Colonies that grew on L agar containing kanamycin and skim milk and produced visible clear zones (i.e., indicating proteolytic activity) in the vicinity of the colonies were picked and streaked on agar plates containing 1.6% (w / v) skim milk. Colonies containing a protease expression cassette with the native rrnIp2 promoter were stored and named strain "SS066". Colonies containing a protease expression cassette with a modified rrnIp2-1 promoter were stored and named strain "SS065".
[0319] Example 3
[0320] Protease expression in Bacillus cells under the control of a modified promoter
[0321] In this example, protease production by two (2) Bacillus cells (i.e., strains SS066 and SS065) containing a protease expression cassette with either the native rrnIp2 promoter (SEQ ID NO: 39) or the modified rrnIp2-1 promoter (SEQ ID NO: 40) was evaluated under small-scale conditions. Both strains were streaked onto L agar plates containing 1.6% (w / v) skim milk and grown at 37°C for approximately twenty-four (24) hours. A single halo-positive colony was inoculated into 25 ml of L broth (1% w / v -1 Tryptone, 0.5% yeast extract w·v -1 、1%NaCl w·v -1 ) and allowed to grow at 37°C (250 RPM) for five (5) hours. This pre-culture was diluted to 0.2 (OD 600 Unit) to 25 ml of MPS2 medium (10% w·v -1 10X MOPS basal medium (8.4% w·v -1 MOPS, 2.9% w·v -1 Sodium chloride, 1.2% w·v -1 Potassium hydroxide, 1% w·v -1 Potassium sulfate, 15w·v -1 Magnesium chloride, 0.7% w·v -1 Quxin (Quxin), 10% w·v -1 Maltrin M150, 10% w·v -1 Micronutrients, 6% w·v -1 Soybean peptone, 0.78% w·v -1 Dipotassium phosphate, 0.3% w·v -1 Urea, 0.2% monopotassium phosphate (pH 7.4, with potassium hydroxide) and grown at 37°C (250 RPM). Micronutrients were made into one (1) liter of 100X stock solution: 400 mg FeSO4 7H2O, 100 mg MnSO4 H2O, 100 mg ZnSO4 7H2O, 50 mg CuCl2 2H2O, 100 mg CoCl26H2O, 100 mg NaMoO4 2H2O, 100 mg Na2B4O710H2O, 10 ml of 1 M CaCl2, and 10 ml of 0.5 M sodium citrate. After forty (40) hours of growth, the protease concentration in the whole cell culture was determined using the suc-AAPF-pNA assay.
[0322] For example, the suc-AAPF-pNA protease assay includes incubating the whole culture fluid with a chromogenic peptide substrate under defined conditions and measuring the color development. The substrate is N-succinyl-L-Ala-L-Ala-L-Pro-L-Phe-p-nitroanilide (suc-AAPF-pNA). After the protease hydrolyzes the peptide substrate, 4-nitroanilide is cut and 4-nitroaniline is produced as a yellow chromophore. Therefore, the absorbance at 405nm is measured and is directly related to the protease level in the analyzed sample. The equipment used for this group of determinations includes a SpectraMAX MTP reader (Model 340-Molecular Device). More specifically, in this assay system, the reagents and solutions used are: (1) N-succinyl-L-Ala-L-Ala-L-Pro-L-Phe-p-nitroanilide (Sigma); (2) dilution buffer: 100 mM Tris-HCl, 10 mM CaCl2, 0.005% 80 buffer (pH 8.6); and (3) Tris buffer: 100 mM Tris-HCl, 0.005% 80 buffer (pH 8.6).
[0323] Therefore, a vial containing 100 mg of suc-AAPF-pNA substrate was dissolved in one (1) ml of DMSO and a one (1) mg / ml working stock solution was prepared by adding one (1) ml of suc-AAPF-pNA to 100 mL of Tris buffer. The protease sample (whole cell culture fluid) was diluted 1000X with dilution buffer. The assay was performed by adding ten (10) μl of diluted protease solution to the wells of the MTP, followed by one hundred and ninety (190) μl of 1 mg / ml working suc-AAPF-pNA substrate solution. The solution was mixed and the absorbance was read at (λ) 405 nm in the MTP reader. A non-protease control was used to correct the background absorbance value. To calculate the protease concentration (mg / L), a dilution series of purified (variant) protease was used as a standard (control sample) and incorporated into the experiment. The relative protease activities are presented in Table 5 below, which shows the (normalized) relative protease expression of SS065 cells (comprising the modified rrnIp2-1 promoter) relative to SS066 cells (comprising the native rrnIp2 promoter), indicating an approximately 2-fold increase in protease activity.
[0324] Table 5
[0325] Small-scale production of proteases
[0326]
[0327] Example 4
[0328] Introduction of heterologous amylase expression cassettes into Bacillus cells
[0329] In this example, a (heterologous) alpha-amylase expression cassette was introduced into a parent Bacillus licheniformis cell. More specifically, the alpha-amylase expression cassette listed below was introduced into a Bacillus licheniformis cell, wherein the cell comprises (a) an expression cassette under the control of the native rrnIp2 promoter (SEQ ID NO: 39) or (b) an expression cassette under the control of a modified rrnIp2-1 promoter (SEQ ID NO: 40). Thus, in this example, Bacillus licheniformis cells containing a plasmid carrying a xylose-inducible comK expression cassette (SEQ ID NO: 43) were grown overnight in fifteen (15) ml of L broth (1% (w / v) tryptone, 0.5% (w / v) yeast extract, 1% (w / v) NaCl) containing one hundred (100) μg / ml spectinomycin dihydrochloride in one hundred twenty-five (125) ml baffled flasks at 37°C and 250 RPM. The overnight culture was diluted to 0.7 (OD) in 25 ml of fresh L broth containing one hundred (100) μg / ml spectinomycin dihydrochloride in two hundred fifty (250) ml baffled flasks. 600 Units). The cells were grown for one (1) hour at 37°C and 250 RPM. D-Xylose was added from a 25% (w / v) stock solution to 0.1% (w / v) and the cells were grown for another four (4) hours at 37°C and 250 RPM. The cells were pelleted at 1700·g for seven (7) minutes. The cells were resuspended in one-quarter (1 / 4) volume of the original culture using the spent culture medium. One hundred (100) μl of the concentrated cells were mixed with approximately one (1) μg of (a) the native rrnIp2 promoter expression construct (SEQ ID NO: 44) or (b) the modified rrnIp2-1 promoter expression construct (SEQ ID NO: 45).
[0330] For example, each box comprises (in the 5' to 3' direction) the same 5'lysA locus homology arm (SEQ ID NO: 46), the natural rrnIp2 promoter (SEQ ID NO: 39) or the modified rrnIp2-1 promoter (SEQ ID NO: 40) that is effectively connected to the modified aprE 5'-UTR (SEQ ID NO: 47). More particularly, International PCT Application No. PCT / US2018 / 049470 (filed on September 5, 2018; incorporated herein by reference in its entirety) further describes the modified aprE 5'-UTR of SEQ ID NO: 47. In addition, the modified 5′-UTR is operably linked to a DNA sequence encoding a lat signal sequence (SEQ ID NO:48), followed by a DNA sequence encoding a (variant) Cytophaga sp. alpha-amylase (SEQ ID NO:49), which is operably linked to a lat terminator sequence (SEQ ID NO:50), which is linked to a 3′ lysA locus homology arm (SEQ ID NO:51).
[0331] The transformation reaction was incubated at 37°C, 1400 RPM for ninety (90) minutes. The cells were washed twice in 1% (w / v) KCl and plated onto TSS agar (50 mM Tris, 37 mM NH4Cl, 1.5 mM K2HPO4·3H2O (pH 7.4), 0.5% (w / v) dextrose, 1 mM MgSO4·7H2O, 0.004% (w / v) FeCl3, 0.004% (w / v) trisodium citrate) containing 1% (w / v) insoluble starch. Transformants were recovered at 37°C.
[0332] Halo positive transformants of rrnIp2_α-amylase (SEQ ID NO:44) and rrnIp2-1_α-amylase (SEQ ID NO:45) expression cassettes were streaked and purified on L agar containing 1% (w / v) insoluble starch to purify single colonies. The sequence of the expression cassette in the purified halo positive colonies was determined by amplifying the expression cassette using the primers listed in Table 6 using standard PCR techniques.
[0333] Table 6
[0334] Forward and reverse primer pairs
[0335] lysA-F GATTTGGGATTTGGAAATCC SEQ ID NO:52 lysA-R CAACACATTGCTTCAGGC SEQ ID NO:53
[0336] Using the primers listed in Table 7, perform Sanger sequencing of the PCR product using standard techniques to verify the sequence of the expression cassette.
[0337] Table 7
[0338] Sequencing primers
[0339] 1032 TCAGAGAGAGACGTATGAGG SEQ ID NO:54 1033 GCATGGACAGGCTTCAACTT SEQ ID NO:55 1034 GGATGTCATTGGCTGGACGA SEQ ID NO:56 1035 TCTACTCCGCCTCTAAATCC SEQ ID NO:57
[0340] A colony with a sequence-verified cassette of the rrnIp2_α-amylase cassette (SEQ ID NO: 44) was stored and named "BF399", and a colony with a sequence-verified cassette of the rrnIp2-1_α-amylase cassette (SEQ ID NO: 45) was stored and named "BF401".
[0341] Example 5
[0342] Heterologous amylase production in Bacillus cells containing an amylase expression cassette
[0343] In this example, applicants assayed a Bacillus strain comprising an α-amylase expression cassette described in Example 4. Therefore, as presented in Table 8 below, the production of α-amylase by the native rrnIp2 promoter (i.e., rrnIp2_α-amylase cassette; SEQ ID NO: 44) and the modified rrnIp2-1 promoter (i.e., rrnIp2-1_α-amylase cassette; SEQ ID NO: 45) were tested to determine the effects of these different promoters on the production of this heterologous protein.
[0344] Table 8
[0345] Strains used to determine α-amylase production
[0346] strain Expression cassette SEQ ID NO BF399 rrnIp2_α-amylase SEQ ID NO:44 BF401 rrnIp2-1_α-amylase SEQ ID NO:45
[0347] The strain was streaked on L broth (1% (w / v) tryptone, 0.5% (w / v) yeast extract, 1% (w / v) NaCl) containing 1% (w / v) insoluble starch, solidified with 1.5% (w / v) Bacto agar, and grown at 37°C for 24 hours. A single colony was inoculated into 4 separate TSB (2% (w / v) non-animal derived peptone, 0.25% (w / v) dextrose, 0.5% (w / v) NaCl, 0.25% (w / v) K2HPO4). The culture was grown at 37°C, 250 RPM and 80% humidity for twenty-four (24) hours. The culture was pelleted at 4000 RPM for seven (7) minutes. Ten (10) μl of each clarified culture supernatant were measured for total protein production in duplicate using the Bradford method using bovine serum albumin (BSA) standards. The relative amylase production of each strain was determined relative to the performance of the strain containing the rrnIp2_α-amylase cassette (SEQ ID NO: 44). More specifically, the relative production of strains containing the native (promoter) rrnIp2_α-amylase cassette (SEQ ID NO: 44) or the modified (promoter) rrnIp2-1_α-amylase cassette (SEQ ID NO: 45) is shown in Table 9 below, and the data in Table 9 show that the amylase produced by the strain containing the modified rrnIp2-1_α-amylase cassette (SEQ ID NO: 45) is 30% higher than the strain containing the native rrnIp2_α-amylase cassette (SEQ ID NO: 44) on average.
[0348] Table 9
[0349] Relative amylase production of strains containing a single copy of the rrnIp2_α-amylase cassette or the rrnIp2-1_α-amylase cassette
[0350] strain Expression cassette SEQ ID NO Relative protein production ± SEM BF399 rrnIp2_α-amylase cassette SEQ ID NO:44 1.00±0.06 BF400 rrnIp2-1_α-amylase cassette SEQ ID NO:45 1.33±0.03
[0351] Example 6
[0352] Introduction of a heterologous pullulanase expression cassette into Bacillus cells
[0353] In this example, a heterologous (truncated) pullulanase expression cassette was introduced into Bacillus licheniformis cells. More specifically, the truncated pullulanase expression cassettes listed below were introduced into Bacillus licheniformis cells, wherein the cells comprised (a) an expression cassette under the control of the native Bacillus licheniformis amyL promoter region (i.e., PamyL-1; SEQ ID NO: 64), (b) an expression cassette under the control of a modified promoter region PamyL-2 (SEQ ID NO: 65), (c) an expression cassette under the control of a modified promoter region PamyL-3 (SEQ ID NO: 66), or (d) an expression cassette under the control of a modified promoter region PamyL-4 (SEQ ID NO: 67).
[0354] Thus, in this example, Bacillus licheniformis cells containing a plasmid carrying a xylose-inducible comK expression cassette (SEQ ID NO: 43) were grown overnight in fifteen (15) ml of L broth (1% (w / v) tryptone, 0.5% (w / v) yeast extract, 1% (w / v) NaCl) containing one hundred (100) μg / ml spectinomycin dihydrochloride in a one hundred twenty five (125) ml baffled flask at 37°C and 250 RPM. The overnight culture was diluted to 0.7 (OD) in 25 ml of fresh L broth containing one hundred (100) μg / ml spectinomycin dihydrochloride in two hundred fifty (250) ml baffled flasks. 600 Units). The cells were grown for one (1) hour at 37°C and 250 RPM. D-Xylose was added from a 25% (w / v) stock solution to 0.1% (w / v), and the cells were grown for an additional four (4) hours at 37°C and 250 RPM. The cells were pelleted at 1700·g for seven (7) minutes. The cells were resuspended in one-quarter (1 / 4) volume of the original culture using the spent culture medium. One hundred (100) μl of the concentrated cells were mixed with approximately one (1) μg of the PamyL-1 expression cassette (SEQ ID NO:78), the PamyL-2 expression cassette (SEQ ID NO:79), the PamyL-3 expression cassette (SEQ ID NO:80), or the PamyL-4 expression cassette (SEQ ID NO:81).
[0355] For example, each cassette comprises (in the 5′ to 3′ direction) the same 5′ lysA locus homology arm (SEQ ID NO:46), the native Bacillus licheniformis promoter region PamyL-1 (SEQ ID NO:64), or one of the following modified promoter region sequences: PamyL-2 (SEQ ID NO:65), PamyL-3 (SEQ ID NO:66), or PamyL-4 (SEQ ID NO:67), wherein the promoter region sequence is operably linked to a DNA sequence encoding a lat signal sequence (SEQ ID NO:48), followed by a DNA sequence encoding a mature and truncated Bacillus debranching pullulanase (SEQ ID NO:68), wherein the DNA sequence encoding a mature and truncated Bacillus debranching pullulanase is operably linked to a lat terminator sequence (SEQ ID NO:50), which is linked to a 3′ lysA locus homology arm (SEQ ID NO:51).
[0356] The transformation reaction was incubated at 37°C, 1400 RPM for ninety (90) minutes. The cells were washed twice in 1% (w / v) KCl and plated onto Minimal agar (50 mM Tris, 37 mM NH4Cl, 1.5 mM K2HPO4·3H2O (pH 7.4), 0.5% (w / v) dextrose, 1 mM MgSO4·7H2O, 0.004% (w / v) FeCl3, 0.004% (w / v) trisodium citrate) containing 0.5% (w / v) Remazol brilliant blue dye starch. Transformants were recovered at 37°C.
[0357] Transformants of the PamyL-1 pullulanase cassette (SEQ ID NO: 78), PamyL-2 pullulanase cassette (SEQ ID NO: 79), PamyL-3 pullulanase cassette (SEQ ID NO: 80), and PamyL-4 pullulanase cassette (SEQ ID NO: 81) were streaked on HI agar to purify single colonies. The sequence of the expression cassette in the purified colonies was determined by amplifying the expression cassette using standard PCR techniques using the primers listed in Table 10.
[0358] Table 10
[0359] Forward and reverse primer pairs
[0360] 447 CTACAGCATGGCCAACAACTA SEQ ID NO:69 674 GTCATGATCTTTTTAACAAAAAAC SEQ ID NO:70
[0361] Using the primers listed in Table 11, perform Sanger sequencing of the PCR product using standard techniques to verify the sequence of the expression cassette.
[0362] Table 11
[0363] Sequencing primers
[0364] 447 CTACAGCATGGCCAACAACTA SEQ ID NO:69 674 GTCATGATCTTTTTAACAAAAAAC SEQ ID NO:70 766 GATTGCTGACGCTGTTATTTGC SEQ ID NO:71 1694 GTAGAAGTTGGTGCCCAGAC SEQ ID NO:72 1695 GGAATACCTATACACAGAAAGCAAC SEQ ID NO:73 1697 CATTCGCATTTGTAGCATACTGCC SEQ ID NO:74 1766 CACGCAAATCTCTGACTTCG SEQ ID NO:75 1767 CAAGCAGCGCCATTAAGTC SEQ ID NO:76 1768 GCAACGACAATAGTTATAATG SEQ ID NO:77
[0365] Colonies with sequence-verified cassettes for the PamyL-1 pullulanase cassette (SEQ ID NO:78), PamyL-2 pullulanase cassette (SEQ ID NO:79), PamyL-3 pullulanase cassette (SEQ ID NO:80), and PamyL-4 pullulanase (SEQ ID NO:81) expression cassettes were streak purified, stored, and named "PamyL-Pulltr.", "LDN461," "LDN462," and "LDN463," respectively.
[0366] Example 7
[0367] Heterologous truncated pullulanase production in Bacillus cells comprising a truncated pullulanase expression cassette
[0368] In this example, applicants assayed Bacillus strains comprising the truncated pullulanase expression cassette described in Example 6. Therefore, as presented in Table 12 below, the production of (truncated) pullulanase of the PamyL-1 pullulanase cassette (SEQ ID NO: 78) and the PamyL-2 pullulanase cassette (SEQ ID NO: 79) was tested to determine the effect of the different promoters and 5'-UTRs on the production of this heterologous pullulanase protein.
[0369] Table 12
[0370] Strains used to assay truncated pullulanase production
[0371] strain Expression cassette SEQ ID NO PamyL-Pulltr. PamyL-1 pullulanase SEQ ID NO:78 LDN461 PamyL-2 pullulanase SEQ ID NO:79
[0372] Likewise, as presented in Table 13 below, the production of (truncated) pullulanase of the PamyL-3 pullulanase cassette (SEQ ID NO:80) and the PamyL-4 pullulanase cassette (SEQ ID NO:81) was tested to determine the effect of the different promoters and 5′-UTRs on the production of this heterologous pullulanase protein.
[0373] Table 13
[0374] Strains used to assay truncated pullulanase production
[0375] strain Expression cassette SEQ ID NO LDN462 PamyL-3 pullulanase SEQ ID NO:80 LDN463 PamyL-4 pullulanase SEQ ID NO:81
[0376] The strain was streaked on L broth (1% (w / v) tryptone, 0.5% (w / v) yeast extract, 1% (w / v) NaCl) solidified with 1.5% (w / v) Bacto agar and grown at 37°C for 24 hours. Three colonies were inoculated in TSB (2% (w / v)), grown overnight at 37°C, 250RPM, and transferred to an undefined medium based on MOPS buffer at 1:10 (v / v) and incubated at 37°C, 250RPM for 68 hours. The culture was harvested and used directly to measure total protein production using the method of Megazyme (PULLULANASE / LIMIT-DEXTRINASEASSAY PROCEDURE) (PullG6 method).
[0377] The relative (truncated) pullulanase production of strain LDN461 (PamyL-2 pullulanase; SEQ ID NO: 79) was determined relative to the performance of strain PamyL-Pulltr (PamyL-1 pullulanase cassette; SEQ ID NO: 78). More specifically, the relative production of the PamyL-Pulltr strain (PamyL-1 pullulanase cassette; SEQ ID NO: 78) and the LDN461 strain (PamyL-2 pullulanase cassette; SEQ ID NO: 79) is shown below in Table 14, which data indicate that the LDN461 strain produced an average of 78% more pullulanase than the PamyL-Pulltr. strain (PamyL-1 pullulanase cassette; SEQ ID NO: 78).
[0378] Table 14
[0379] Relative pullulanase production of strains containing a single copy of the PamyL-1 pullulanase cassette or the PamyL-2 pullulanase cassette
[0380] strain Expression cassette SEQ ID NO Relative protein production ± SEM PamyL-Pulltr. PamyL-1 pullulanase SEQ ID NO:78 1.00±0.05 LDN461 PamyL-2 pullulanase SEQ ID NO:79 1.78±0.05
[0381] Likewise, the relative (truncated) pullulanase production of strain LDN463 (PamyL-4 pullulanase cassette; SEQ ID NO:81) was determined relative to the performance of strain LDN462 (PamyL-3 pullulanase cassette; SEQ ID NO:80), wherein the relative production of the strains is shown in Table 15 below, the data of which show that strain LDN463 (PamyL-4 pullulanase cassette) produced an average of 16% more (truncated) pullulanase than strain LDN462 (PamyL-3 pullulanase cassette; SEQ ID NO:80).
[0382] Table 15
[0383] Relatively truncated pullulanase production by strains containing a single copy of the PamyL-3 pullulanase cassette or the PamyL-4 pullulanase cassette
[0384] strain Expression cassette SEQ ID NO Relative protein production ± SEM LDN462 PamyL-3 pullulanase SEQ ID NO:80 1.00±0.03 LDN463 PamyL-4 pullulanase SEQ ID NO:81 1.16±0.07
[0385] References
[0386] International PCT Application No.PCT / US 2018 / 049470
[0387] International PCT Publication No.WO 2003 / 083125
[0388] International PCT Publication No.WO 2003 / 089604
[0389] International PCT Publication No.WO 2013 / 086219
[0390] Botstein and Shortle,Science 229:4719,1985.
[0391] Brode et al., "Subtilisin BPN'variants: increased hydrolytic activity on surface-bound substrates via decreased surface activity", Biochemistry, 35(10):3162-3169, 1996.
[0392] Caspers et al., "Improvement of Sec-dependent secretion of aheterologous model protein in Bacillus subtilis by saturation mutagenesis of the N-domain of the AmyE signal peptide", Appl. Microbiol. Biotechnol., 86(6):1877-1885, 2010.
[0393] Chang et al.,Mol.Gen.Genet.,168:11-115,1979.
[0394] Devereux et al.,Nucl.Acid Res.,12:387-395,1984.
[0395] Earl et al.,“Ecology and genomics of Bacillus subtilis”,Trends inMicrobiology.,16(6):269-275,2008.
[0396] Ferrari et al.,"Genetics,"in Harwood et al.(ed.),Bacillus,PlenumPublishing Corp.,1989.
[0397] Ferrari et al.,"Genetics,"in Harwood et al.(ed.),Bacillus,PlenumPublishing Corp.,1989.
[0398] Fisher et.al.,Arch.Microbiol.,139:213-217,1981.
[0399] Hamoen et al.,“Controlling competence in Bacillus subtilis:sharedused of regulators”,Microbiology,149:9-17,2003.
[0400] Hamoen et al.,Genes Dev.12:1539-1550,1998.
[0401] Higuchi et al.,Nucleic Acids Research 16:7351,1988.
[0402] Ho et al.,Gene 77:61,1989.
[0403] Hoch et al.,J.Bacteriol.,93:1925-1937,1967.
[0404] Hopwood,The Isolation of Mutants in Methods in Microbiology(J.R.Norris and D.W.Ribbons,eds.)pp 363-433,Academic Press,New York,1970.
[0405] Horton et al.,Gene 77:61,1989.
[0406] Iglesias and Trautner,Molecular General Genetics 189:73-76,1983.
[0407] Jensen et al.,“Cell-associated degradation affects the yield ofsecreted engineered and heterologous proteins in the Bacillus subtilisexpression system”Microbiology,146(Pt 10:2583-2594,2000.
[0408] Liu and Zuber,“A Molecular Switch Controlling Competence andMotility:Competence Regulatory Factors ComS,MecA,and ComK Control DependentGene Expression in Bacillus subtilis”,J.Bacteriology,180(16):4243-4251,1998.
[0409] Lo et al.,Proceedings of the National Academy of Sciences USA 81:2285,1985.
[0410] Mann et al.,Current Microbiol.,13:131-135,1986.Holubova,1985;
[0411] McDonald,J.Gen.Microbiol.,130:203,1984.
[0412] Needleman and Wunsch,J.Mol.Biol.,48:443,1970.
[0413] Olempska-Beer et al.,“Food-processing enzymes from recombinantmicroorganisms--a review”’Regul.Toxicol.Pharmacol.,45(2):144-158,2006.
[0414] Palmeros et al.,Gene 247:255-264,2000.
[0415] Pearson and Lipman,Proc.Natl.Acad.Sci.USA 85:2444,1988.
[0416] Perego,1993,In A.L.Sonneshein,J.A.Hoch,and R.Losick,editors,Bacillussubtilis and Other Gram-Positive Bacteria,Chapter 42,American Society ofMicrobiology,Washington,D.C.
[0417] Raul et al.,“Production and partial purification of alpha amylasefrom Bacillus subtilis(MTCC 121)using solid state fermentation”,BiochemistryResearch International,2014.
[0418] Sarkar and Sommer,BioTechniques 8:404,1990.
[0419] Saunders et al.,J.Bacteriol.,157:718-726,1984.
[0420] Shimada,Meth.Mol.Biol.57:157;1996.
[0421] Smith and Waterman,Adv.Appl.Math.,2:482,1981.
[0422] Smith et al.,Appl.Env.Microbiol.,51:634 1986.
[0423] Solberg and Krauss,“Luciferase assay to study the activity of acloned promoter DNA fragment”,Methods Mol Biol.977:65-78,2013.
[0424] Stahl et al,J.Bacteriol.,158:411-418,1984.
[0425] Van Dijl and Hecker,“Bacillus subtilis:from soil bacterium to super-secreting cell factory”,Microbial Cell Factories,12(3).2013.
[0426] Vorobjeva et al.,FEMS Microbiol.Lett.,7:261-263,1980.
[0427] Westers et al.,“Bacillus subtilis as cell factory for pharmaceuticalproteins:a biotechnological approach to optimize the host organism”,Biochimica et Biophysica Acta.,1694:299-310,2004.
[0428] Youngman et al.,Proc.Natl.Acad.Sci.USA 80:2305-2309,1983.
Claims
1. A promoter nucleic acid which differs from SEQ ID NO:39 in that the C at nucleotide position 30 of SEQ ID NO:39 is mutated to T, the A at nucleotide position 89 of SEQ ID NO:39 is mutated to T, the A at nucleotide position 90 of SEQ ID NO:39 is mutated to G, and the A at nucleotide position 91 of SEQ ID NO:39 is mutated to T.
2. The promoter nucleic acid according to claim 1, which is operably linked to a gene or an open reading frame encoding a protein of interest located 3' downstream of the promoter.
3. A promoter nucleic acid consisting of SEQ ID NO:
40.
4. The promoter nucleic acid according to claim 3, which is operably linked to a gene or an open reading frame encoding a protein of interest located 3' downstream of the promoter.
5. A polynucleotide comprising the promoter nucleic acid of claim 1 or claim 3 and a gene or an open reading frame encoding a target protein located 3' downstream thereof and operably linked thereto. The polynucleotide of claim 5 , wherein the protein of interest is an enzyme.
7. The polynucleotide of claim 6, wherein the enzyme is a hydrolase.
8. A modified Bacillus sp. cell comprising the promoter nucleic acid of any one of claims 1-4.
9. A modified Bacillus sp. cell comprising the polynucleotide of any one of claims 5-7.
10. An expression cassette comprising the promoter nucleic acid of any one of claims 1 to 4, or the polynucleotide of any one of claims 5 to 7.
11. A modified Bacillus sp. cell comprising the expression cassette of claim 10.
12. A method for enhanced protein production in a modified Bacillus sp. cell, the method include: (a) introducing a polynucleotide expression cassette into a parent Bacillus sp. cell, wherein the expression cassette comprises a promoter sequence located 5′ upstream of a gene or open reading frame encoding a protein of interest and operably linked to the gene or open reading frame encoding the protein of interest, wherein the promoter sequence differs from SEQ ID NO: 39 in that: the C at nucleotide position 30 of SEQ ID NO: 39 is mutated to T, the A at nucleotide position 89 of SEQ ID NO: 39 is mutated to T, the A at nucleotide position 90 of SEQ ID NO: 39 is mutated to G, and the A at nucleotide position 91 of SEQ ID NO: 39 is mutated to T; (b) isolating the modified cell comprising the introduced expression cassette from step (a); and (c) fermenting the modified cells of step (b) under conditions suitable for producing the protein of interest, wherein the modified cells of step (c) produce an increased amount of a protein of interest relative to an equivalent Bacillus species cell, the equivalent Bacillus species cell comprising a polynucleotide expression cassette comprising a promoter sequence located 5′ upstream of and operably linked to the same gene or open reading frame encoding the same protein of interest, wherein the promoter is SEQ ID NO:
39.
13. The method of claim 12, wherein the target protein is an enzyme.
14. The method of claim 13, wherein the enzyme is a hydrolase.
